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The last decades have shown an increasing interest in treatment of high blood 
pressure. Copious amounts of data have been published on the mortality and 
morbidity risks of high blood pressure. [1] Overall these data have resulted in an 
increasing awareness of the deleterious effects of only modest elevation of blood 
pressure on morbidity and mortality. Moreover, treatment of high blood pressure 
resulted in substantial benefits in terms of reduced morbidity and mortality. [2-
6] This has resulted in official guidelines about treatment for hypertension that 
have become stricter with every decade. However, most of the evidence has been 
generated from middle-aged people. Only a few trials have included people of 
80 year and older. [7-9] Looking at the results in detail within that age group the 
evidence is not robust. Given the increasing lifespan worldwide, physicians are 
confronted with many elderly patients over eighty. Hence, there is an increasing 
urge to generate more knowledge in regard to the effects of high blood pressure 
in the elderly.
Even in ancient times, high blood pressure has been recognized as a potential 
health threat. In the Yellow Emperor’s Classics of Internal Medicine, the following 
answers were given to the plain questions of the emperor of China, 2600 B.C [10]: 
“The blood current flows continuously in a circle and never stops.”
“When the heart pulse beats vigorously and the strokes markedly 
prolonged, the corresponding illness makes the patient unable to speak.”
“If too much salt is used in food, the pulse hardens.”
More than 4000 years elapsed before William Harvey in 1628 proved the circulation 
of the blood; still later the sequence of hypertension, cerebral haemorrhage, and 
aphasia was recognized. [11] A hundred years later, Stephen Hales managed 
to measure systolic arterial blood pressure and the effect of haemorrhage on 
arterial blood pressure. [12] He also determined that the capillary arteries were 
the site of the chief peripheral resistance. The latter observation remains a basic 
concept in modern human physiology. In the early nineteenth century it became 
possible to measure blood pressure with a mercury manometer; it was used until 
1896 when Scipione Riva-Rocci of Turin designed the first clinically acceptable 
sphygmomanometer. [13] In 1905 Korotkoff reported the now standard clinical 




At the beginning of the twentieth century there were three schools of thought 
with reference to the pathogenesis of hypertension. [15] First, the school of Bright 
that believed that essential hypertension was due to renal disease. [16] In 1827 
Bright associated hardness and fullness of the pulse with albuminuria, edema and 
hypertrophy of the left ventricle with contracted kidneys. Thus, Bright introduced 
the concept of renal disease at the base of cardiovascular disease. Second, the school 
of Gull and Sutton believed that primary generalized arteriocapillary fibrosis 
caused contracted kidneys and left ventricular hypertrophy causing hypertension. 
[17] Hence regarding hypertension as the result of widespread vascular disease. 
Third, the school of Huchard and Allbutt making the statement that hypertension 
could occur without renal disease. [18,19] Years before, Mahomed had already 
published his clinical observation showing that high arterial blood pressure could 
exist without albuminuria. [20] Due to his untimely death, it wasn’t until Huchard 
and Allbutt’s finding that it was more widely established that arteriosclerosis 
and hypertension were independently associated diseases. These concepts were 
evaluated further in the early thirties of the 20th century mainly after Goldblatt 
could make dogs hypertensive after constricting their renal arteries. [21] In 1940, 
this resulted in the discovery of renin and finally in the discovery of the renin-
angiotensin system. Nowadays many forms of secondary hypertension have been 
acknowledged, but the most frequent diagnosis remains essential hypertension. 
Though the pharmacological treatment has expanded explosively, still no definite 
pathophysiological process has been recognized as the sole determinant of 
essential hypertension.
Although high blood pressure was known to have deleterious effects on health, the 
ultimate prognosis was considered to be different according to the underlying cause 
of hypertension. For example, in 1953 the arteriosclerotic form of hypertension in 
the elderly associated with arteriosclerosis of the large vessels, e.g. resulting in a 
wide pulse pressure, was supposed to have a benign prognosis. [22] Presently this 
is recognized as a common, but by no means, benign form of hypertension and 
referred to as isolated systolic hypertension. [23] Up to the late seventies of the 
20th century only diastolic blood pressure was considered to be detrimental and 
was used to classify subjects who suffer from hypertension. [24] Later on, systolic 
blood pressure became recognized as an even stronger predictor of morbidity and 




pressure should be attained lower than 140 mmHg and for individuals with renal 
disease and diabetes even lower than 130 mmHg, irrespective of age. [23] 
According to the recent guidelines, hypertension has a very high prevalence 
amongst elderly. [23] In the Framingham study one could discern the average 
diastolic and systolic blood pressure increased up to the sixth decade resulting in 
a prevalence of hypertension up to 40% at the age of sixty. [25,26] From that point 
on the systolic blood pressure continued to rise up to the eighth decade, however 
the diastolic blood pressure started to decline. 
Figure 1. Average age trends in (a) systolic and (b) diastolic blood pressure levels for 
men and women based on cross-sectional (dotted lines) and longitudinal (cohort, 
unbroken lines) data on participants in the Framingham Study. [26]
















In another report the prevalence of hypertension reached 60% in persons aged 
85 and over. [27] Given this high prevalence, many are reluctant in accepting the 
strict criteria for high blood pressure at middle age for people at old age, as most 
of the population eventually will fulfil these criteria. 
It is argued that a high blood pressure at old age might have a different effect on 
health compared to same levels of blood pressure in the middle aged. This has been 
proven for other cardiovascular risk factors also. For example in persons aged 85 
years and older total cholesterol levels were no longer related to mortality. [28] 
Additionally observational data have shown that high blood pressure in elderly 
persons; above 80 years is no longer a risk factor for mortality. [27, 29, 30] Placebo-
controlled clinical trials are not conclusive. Few subjects older than 80 years are 
included in these studies [2-6, 8]. An open-randomised trial has been published 
with patients exclusively over eighty years old. [7] In the treated group there was 
a non-significant increase in mortality that completely nullified the significant 
reduction in strokes. In contrast, the HYVET study, a placebo controlled double 
blind trial in persons aged 80 years and older, was prematurely stopped after 
safety analysis showed excess mortality in the placebo group. [9] 
The differences in outcome between the observational and interventional studies 
at old age versus younger age are difficult to understand. In younger subjects 
the observational studies are in line with the intervention studies. A high blood 
pressure is related with greater mortality/morbidity and lowering high blood 
pressure reduces the mortality/morbidity. It is counterintuitive that high blood 
pressure at old age suddenly appeared not to be a risk factor; even more, that 
treatment of high blood pressure at old age may prove harmful. Possibly the 
elderly, as a group, are not so heterogeneous compared to the middle aged 
people. Treatment of high blood pressure in more diseased elderly might have 
more harmful effects compared to treatment in less diseased elderly. In younger 
age groups who are more vascular diseased, it has been reported that treatment 
for high blood pressure resulting in low diastolic blood pressure might give 
excess morbidity and mortality as well. [31, 32] In this thesis we have explored 
the predictive value of blood pressure and the possible underlying mechanism 




introduction, a prognosis part, an etiological insight part, a general discussion and 
a summary. 
Prognosis:
Is high blood pressure at older age associated with adverse outcomes, 
including cardiovascular mortality, renal failure and cognitive decline? 
Etiological insights:
What is the association between blood pressure and cardiac function at 
older age? 
We have used data of the Leiden 85-plus Study and the Rotterdam Study. The 
Leiden 85-plus Study was a prospective population-based study of all 85 years 
old inhabitants of Leiden, The Netherlands.[33] Between September 1997 and 
September 1999 all 705 members of the 1912 to 1914-birth cohort in the city of 
Leiden were asked to participate in this study in the month after their 85th birthday. 
There were no selection criteria related to health or demographic characteristics. 
At baseline, 85 year old participants were visited at their place of residence. 
During these visits blood pressure was measured twice, an electrocardiogram 
recorded, a face-to-face interview taken and performance tests were conducted. 
The participants were annually visited up to age 90 years old. At this age, a 
sample was invited to the study-centre for an echocardiographic examination. 
The collected data provided unique opportunities to examine population wise the 
effects of blood pressure at old age. 
The Rotterdam Study is a large, prospective, population-based cohort study 
conducted in all inhabitants aged 55 and older of Ommoord, a district of Rotterdam, 
The Netherlands. [34] Of 10,275 eligible subjects, 7,983 (77.7%) participated in the 
baseline examinations between 1990 and 1993 (mean age 71.2±25.2, range 55–106). 
All participants were interviewed at home and visited the research centre for 
further examinations. At the fourth survey (2002–2004), cognitive function was 
extensively assessed using a dedicated neuropsychological test battery.
In the first part three studies on prognosis of blood pressure are presented. 
Chapter two presents the association between blood pressure at age 85 years and 
mortality in the following 5 years. Chapter three presents the association between 
Chapter 1
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blood pressure and creatinine clearance at the age of 85 years up to the age of 
90 years. Chapter four describes the association between blood pressure and 
cognitive function over time. In the second part, three etiological oriented studies 
are presented. Chapter five describes the prevalence of cardiac valve dysfunction 
in participants aged 90 years. Chapter six describes the association between blood 
pressure and cardiac function at the age of 90 years. Chapter seven studies the 
possible connection between the autonomous nervous system and mortality in 
subjects 85 years and older. The eighth chapter contains a general discussion of 
the preceding studies chapters and their possible implications for care of older 
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In a population-based prospective study no 
association between high blood pressure and 
mortality after age 85 years.
Thomas van Bemmel, MD, Jacobijn Gussekloo, MD PhD, Rudi GJ Westendorp, MD 
PhD, Gerard J Blauw, MD PhD
Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 
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Objective: To study the impact of a history of hypertension and current blood 
pressure on mortality in the oldest old. 
Design: An observational population-based cohort study.
Setting: Community city of Leiden, the Netherlands.
Participants: Five hundred and ninety-nine inhabitants of the birth-cohort 1912-
1914 were enrolled on their 85th birthday. There were no selection criteria related 
to health or demographic characteristics.
Interventions: The mean follow-up was 4.2 years. The medical histories were 
obtained from general practitioners. Medication histories were obtained from the 
participant’s pharmacist. Blood pressure was measured twice at baseline.
Main outcome measures: All cause and cardiovascular mortality.
Results: Five hundred and seventy-one participants were included, 39.2% 
had a history of hypertension. During follow-up 290 participants died, 119 
due to cardiovascular causes. Compared to participants without a history of 
hypertension, those with a history of hypertension had increased mortality from 
cardiovascular causes [relative risk (RR) 1.60, confidence interval (CI) 1.06-2.40] 
but equal mortality from all causes (RR 1.19, CI 0.91-1.55). High blood pressure at 
baseline (age 85) was not a risk factor for mortality. Baseline blood pressure values 
below 140/70 mmHg (n=48) were associated with excess mortality, predominantly 
in participants with a history of hypertension.
Conclusion: In the oldest old, high blood pressure is not a risk factor for mortality, 
irrespective of a history of hypertension. Blood pressure values below 140/70 are 
associated with excess mortality. 




The role of high blood pressure as a risk factor for morbidity and mortality 
in the oldest old is still subject to debate, despite the fact that people aged 85 
years and older often have a history of hypertension [1-9]. The relatively scarce 
observational data in people aged 80 years and over are contradictory, showing 
either an increased risk or an inverse relationship for high blood pressure with 
mortality [4-8].
Some of the different results found might be due to the differences between current 
blood pressure and former blood pressure [5]. Normal blood pressure in the face 
of a longstanding history of hypertension might have a considerable different 
impact on prognosis than high blood pressure without a history of hypertension. 
Placebo-controlled clinical trials are also inconclusive, because hardly any 
subjects older than 80 years are included in these studies [2,10-14]. The only study 
designed for people older than 80 years reported a reduced risk for strokes but 
an increased total mortality rate in the actively treated group [2]. Those findings 
could be arguments for clinicians to be reluctant to treat high blood pressure in 
old age. 
The aim of the present study was to disentangle the relationship between a 
positive history of hypertension and current blood pressure in very old men and 
women participating in the population-based Leiden 85-plus Study. With this 
study we elaborate on the previous findings in the former cohort of the Leiden 
85-plus Study, showing that elevated blood pressure was associated with better 





The Leiden 85-plus Study is a prospective population-based study of all 85-year 
old inhabitants of Leiden, The Netherlands. The study design and characteristics 
of the cohort have been described in detail previously [15,16]. In short, between 
September 1997 and September 1999 all 705 members of the 1912 to 1914-birth 
cohort in the city of Leiden were asked to participate in the month after their 
85th birthday. There were no selection criteria related to health or demographic 
characteristics. 
At baseline, 85-year old participants were visited three times at their place of 
residence to administer extensive data on health, functioning and well-being. In 
addition, a medical history was obtained from participant’s general practitioner or 
nursing home physician, and information on the use of medication was obtained 
from participant’s pharmacist. Participants gave oral informed consent and 
for people who were severely cognitively impaired, a guardian gave informed 
consent. The Medical Ethics Committee of the Leiden University Medical Center 
approved the study. 
History of hypertension and baseline blood pressure 
The definition of a positive history of hypertension was fulfilled when at baseline 
the diagnosis hypertension could be obtained from the medical records. This was 
assessed independently of the baseline blood pressure (age 85 years). 
An experienced research nurse measured blood pressure twice at baseline with a 
mean interval of 2 weeks. Blood pressure was measured in seated position after at 
least 5 min of rest and no vigorous exercise during the preceding 30 min. The cuff 
was inflated to 30 mmHg above the pressure after the disappearance of the radial 
pulse. The systolic value was measured at the onset of Korotkoff phase 1 and the 
diastolic value was measured at the onset of Korotkoff phase 5. For the analysis of 
blood pressure we used the mean of the measured systolic values and the mean of 
the measured diastolic blood pressures. 




All participants were followed for mortality up until the censor date (1 April 
2004). Shortly after the civil registry reported the death of a participant, the 
general practitioner or nursing home physician was interviewed to obtain the 
specific cause of death. Two senior specialists of internal medicine determined 
the primary causes of death by consensus without knowledge of medical history 
and the research aims. Primary causes of death were classified according to the 
tenth version of the International Classification of Diseases (ICD-10) [17] and were 
divided into two groups: cardiovascular mortality (ICD-codes I00-I99, I20-I25 and 
I60-I69) and non-cardiovascular mortality (all other ICD-codes).
Demographic and clinical characteristics
At baseline, a research nurse collected information concerning the demographic 
characteristics. Low education was defined as primary school only. At baseline 
the Mini-Mental State Examination (MMSE) was administered to screen for 
cognitive impairment [18]. Disability in basic activities of daily living (ADL) and 
instrumental activities of daily living (IADL) were assessed with the Groningen 
Activity Restriction Scale [19]. The presence of cardiovascular disease was defined 
as a previous history of cerebrovascular accident, angina pectoris, myocardial 
infarction, peripheral vascular disease or an electrocardiogram revealing 
myocardial ischaemia or infarction (Minnesota codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 
5-2 and 5-3) [20]. The presence of chronic disease was defined as a previous history 
of diabetes, Parkinson’s disease, chronic obstructive pulmonary disease, arthrosis, 
or malignancies. Angiotensin converting enzyme inhibitors, angiotensin-1 
receptor blockers, thiazide diuretics, dihydropyridin calcium channel blockers or 
β-blockers with the exclusion of sotacor, were classified as antihypertensive drugs.
Baseline blood pressure categories
According to national and international guidelines, we categorized the participants 
for both systolic and diastolic blood pressure in three clinically relevant groups, 
namely a systolic blood pressure lower than 140 mmHg (normal blood pressure), 
140-159 mmHg (hypertension stage 1) and 160 mmHg and over (hypertension 
stage 2) [21]. For diastolic blood pressure we used lower than 70 mmHg (low 
blood pressure), 70-89 mmHg (normal blood pressure) and 90 mmHg and over 




Distributions of categorical clinical characteristics were compared with chi-
squared tests, and continuous data were compared with independent t-tests. 
Mortality risks and 95% confidence intervals for participants with hypertension 
versus those without a history of hypertension were estimated in a Cox 
proportional-hazards model. We adjusted the mortality risks for gender, number 
of used antihypertensive medications and the presence of cardiovascular disease, 
because these determinants were differently distributed in the participants 
with and without a history of hypertension. The association between all-cause 
mortality and systolic and diastolic blood pressure was first visualized by use of 
Kaplan- Meier analyses, and differences were tested by log-rank tests. Mortality 
risks and 95% confidence intervals depending on systolic and diastolic blood 
pressure were estimated in a Cox proportional-hazards model. We adjusted the 
mortality risks for gender, use of antihypertensive medication and the presence 
of cardiovascular disease. To estimate the absolute risks of mortality, mortality 
rates and corresponding 95% confidence intervals were calculated by life tables 
for strata of systolic and diastolic blood pressure. All analyses were performed 
with SPSS version 12.01 (SPSS Inc., Chicago, Illinois, USA).
Results
Of the 705 eligible participants, 14 died before they could be enrolled and 92 
refused to participate, resulting in a cohort of 599 participants (87% response). 
In the present analyses we included only the 571 participants for whom two 
measurements of blood pressure at baseline were available. 
At baseline, 224 participants (39.2%) had a history of hypertension according to 
the medical records of their general practitioner or nursing home doctor. The 
history of hypertension was equally distributed for gender and education (Table 
1). There were no differences in daily functioning (both ADL and IADL), cognitive 
function and the presence of chronic diseases for those with and without a history 
of hypertension (Table 1). Participants with a history of hypertension more often 
had a history of cardiovascular disease compared to participants without a history 
No association between high blood pressure and mortality.
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of hypertension (71 versus 58%, chi-squared P ≤ 0.001). Some 62% (n=138) of the 
participants with a history of hypertension used one or more antihypertensive 
drugs. Specific medications that were used included (combinations of) 
β-blockers (n=57, 41%), thiazide diuretics (n=55, 40%), dihydropyridin calcium 
channel blockers (n=36, 26%), angiotensin converting enzyme inhibitors and 
angiotensin-1 receptor blockers (n=45, 33%). Of the participants without a history 
of hypertension, some 20% used one or more of the aforementioned drugs for 
other diagnosis, as was verified by the general practitioners.
For participants with a history of hypertension, the mean baseline systolic blood 
pressure was 157.3 mmHg [standard deviation (SD) 18.3] versus 153.7 mmHg (SD 
19.1) in those without a history of hypertension (independent t-test, P = 0.03). 
In total, 210 participants (36.8 %) had a systolic blood pressure at age 85 of 160 
mmHg or higher. The mean diastolic blood pressure at age 85 was 77.0 mmHg 
(SD 9.9) in participants with a history of hypertension versus 75.8 mmHg (SD 9.2) 
in those without a history of hypertension (independent t-test, P = 0.01). In total, 
48 participants (8.4 %) had a mean diastolic blood pressure above 90 mmHg at 
age 85.
Table 1 Clinical characteristics at baseline of 571 participants at age 85 years, according 
to a history of hypertension.
History of Hypertension
Present (n=224) Absent (n=347)
Females 160 (71%) 221 (64%)
Low education (%) 151 (68%) 219 (64%)
ADL independency (%) 105 (47%) 154 (45%)
IADL independency (%) 56 (25%) 91 (26%)
Cognitive function
 MMSE > 27 points (%) 78 (35%) 124 (36%)
 MMSE < 19 points (%) 34 (15%) 58 (17%)
Mean systolic blood pressure (SD) (mmHg) 157.3 (18.3)* 153.7 (19.1)
Mean diastolic blood pressure (SD) (mmHg) 77.0 (9.9)* 75.8 (9.2)
History of chronic disease (%) † 131 (59%) 200 (58%)
History of cardiovascular disease (%) ‡ 160 (71%)** 200 (58%)
ADL, basic activities of daily livibg; IADL, instrumental activities of daily living; MMSE, 
Mini -Mental State Examination; SD, standard deviation. * independent t-test P ≤ 0.03, **chi-
squared, P ≤ 0.001, † Including diabetes, Parkinson’s disease, chronic obstructive pulmonary 
disease, arthrosis (including rheumatoid arthritis and polymyalgia rheumatica), and 
malignancies. ‡ Including cerebrovascular accident, angina pectoris, myocardial infarction, 




During a median follow-up of 4.2 years, 290 participants died. One hundred 
and nineteen participants died from cardiovascular causes and 164 from non-
cardiovascular causes; causes of death could not be obtained for 7 participants. 
Participants with a history of hypertension did not have an increased all-cause 
mortality risk compared to those without a history of hypertension [adjusted 
relative risk (RR) 1.19, 95% confidence interval (CI) 0.91-1.55], but they did 
have a 1.6-fold increased cardiovascular mortality risk (95% CI 1.06-2.40). There 
was no association between a history of hypertension at age 85 years and non-
cardiovascular mortality (Table 2).
Table 2 Mortality risks depending on history of hypertension at age 85 years.
History of hypertension
Present (n=224) Absent * (n=347)
All causes († 290) 1.17 (0.90-1.53) 1
        Cardiovascular († 119) 1.54 (1.03-2.32) 1
        Non-cardiovascular († 164) 0.97 (0.68-1.39) 1
Mortality risks and corresponding 95% confidence intervals were estimated with Cox 
proportional hazards model adjusted for gender, number of antihypertensive medications 
and presence of cardiovascular disease. † Observed Number of deaths; * Reference category; 
n = number of participants.
Figure 1 presents the cumulative mortality depending on categories of systolic 
and diastolic blood pressure at baseline. A significantly gradual inverse relation 
appeared between all-cause mortality and systolic blood pressure. Participants 
(n=129) with a diastolic blood pressure at baseline below 70 mmHg had a higher 
all-cause mortality compared to those in the other two categories of diastolic 
blood pressure. 
Table 3 presents the all-cause mortality risks dependent on categories of 
systolic and diastolic blood pressure at baseline, adjusted for gender, number of 
antihypertensive medications and presence of cardiovascular disease. Compared 
to participants with a systolic blood pressure between 140 and 159 mmHg and a 
diastolic blood pressure between 70 and 89 mmHg (reference group) a 2.3-fold 
increased mortality risk was found for participants with a blood pressure lower 
than 140/70 mmHg (95% CI 1.61-3.38). 
No association between high blood pressure and mortality.
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Figure 1: Cumulative all cause mortality depending on systolic and diastolic blood 
pressure at age 85.
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Table 3: Number of participants rates (number of deaths) and relative risks (RR) for 
all cause mortality dependent on categories of systolic and diastolic blood pressure at 
baseline.
Systolic BP (mmHg)
Diastolic BP (mmHg) < 140 140 - 159 ≥ 160
< 70 
No. participants (no. deaths) 48 (40) 68 (37) 13 (7)
RR (95% CI) 2.33 (1.61-3.38) 1.04 (0.71-1.53) 1.14 (0.52-2.46)
70 – 89 
No participants (no. deaths) 56 (31) 180 (93) 158 (58)
RR (95% CI) 1.19 (0.79-1.79) 1* 0.66 (0.47-0.92)
≥ 90
No participants (no. deaths) 0 9 (6) 39 (18)
RR (95% CI) 1.65 (0.72-3.78) 0.82 (0.50-1.36)
BP, blood pressure. Mortality risks and corresponding 95% confidence intervals (CI) 
were estimated with Cox proportional-hazards model adjusted for gender, number of 
antihypertensive medications and presence of cardiovascular disease. *, Reference category.
To investigate whether poor general health might be confounding this result an 
additional adjustment for the presence of chronic diseases, MMSE, ADL and IADL 
was performed. The increased mortality risk for participants with a blood pressure 
lower than 140/70 mmHg remained significant (RR 1.51, 95% CI 1.03-2.23). For 
participants with a systolic blood pressure equal to and higher than 160 mmHg 
and a diastolic blood pressure between 70 and 89 mmHg, a survival benefit was 
found compared to the reference group (RR 0.66, CI 0.47-0.92). However, after the 
additional adjustment for poor general health, this survival benefit disappeared 
(RR 0.73, 95% CI 0.52-1.02).
The absolute mortality rates dependent on blood pressure at age 85 stratified 
for the history of hypertension are presented in Table 4. In both strata, all-cause 
mortality was highest for participants with low blood pressure (systolic blood 
pressure below 140 mmHg or diastolic blood pressure below 70 mmHg) and most 
pronounced in participants with a history of hypertension and a low systolic blood 
pressure. In the group of participants with a systolic blood pressure lower than 
140 mmHg, participants with a history of hypertension had a significant higher 
all-cause mortality rate (29.1 per 100 person years, 95% CI 19.4-38.9) compared to 
those without a history of hypertension (14.6 per 100 person years, 95% CI 9.9-
19.3). 


























































































































































































































































































































































































































































































































































































Within the participants with blood pressures lower than 140/70 mmHg at 
baseline, the amount of cardiovascular disease was not uniformly divided. Of the 
48 participants, 16 had a positive history of hypertension. Cardiovascular disease 
was present in 14 (87.5%) participants with a history of hypertension compared to 
18 (56.3%) of the 32 participants without a history of hypertension (chi squared, 
P = 0.03). 
Discussion 
The main finding of this prospective population-based study was, that at the 
age of 85 years and over, high blood pressure was not associated with increased 
mortality, independently of the history of hypertension. Moreover, subjects with 
low systolic and diastolic blood pressure had an increased mortality risk.  
Except for the lowest range of blood pressures, we did not find a relationship 
between blood pressure and mortality in participants aged 85 years and 
over, despite the fact that a history of hypertension remained a risk factor for 
cardiovascular mortality in this age group. This is different from reports in 
younger age groups, where those with the highest blood pressure are at the highest 
mortality risk [1,10-13,22]. The finding that low blood pressure is associated with 
an increased mortality risk in the oldest old corroborates with earlier results from 
the Leiden 85-plus Study and other reports [4-6,8,23,24].
The crude results from both cohorts of the Leiden 85-plus Study are similar. Both 
studies showed a higher mortality for participants in the low blood pressure 
group. However, in the present study the higher mortality was especially apparent 
for the participants with a history of hypertension. Secondly, in the present study 
systolic and diastolic blood pressure were analysed together in blood pressure 
categories according to international guidelines [21]. This was done because a low 
diastolic blood pressure in the presence of a high systolic blood pressure might 
have a different aetiology and thus prognosis, e.g. high atherosclerotic burden, 
than the same low diastolic blood pressure with a low systolic blood pressure, 
e.g. heart failure [25]. This was confirmed by the finding that a low diastolic blood 
No association between high blood pressure and mortality.
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pressure is only harmful in the presence of a low systolic blood pressure in the 
very old. 
How can we explain the results? Hypertension is a well-known risk factor for 
heart failure. Possibly, longstanding hypertension leads to preclinical heart failure 
that might lower actual blood pressure and therefore could be partly responsible 
for our finding [26]. Nevertheless, it cannot be excluded that blood pressure-
lowering therapy contributed to the inverse relation between low blood pressure 
and mortality risk. 
The strength of the present study is that it seems to reflect the history of elderly 
individuals with different levels of blood pressure, given the population-based 
character, the 87% enrolment of the 85-year-olds and the small number of 
individuals who were lost to follow-up. Its weakness is that it relies on a baseline 
assessment of blood pressure. Another possible weakness might be the lack of 
uniformity for a positive history of hypertension. It could be that the general 
practitioners used variable criteria for a former diagnosis of hypertension. 
Moreover, because of the observational nature of the data, we cannot exclude 
that residual confounding is at play and therefore we are not able to draw final 
conclusions on causality.
From the present study, the clear message is that in the oldest old, blood pressure 
is not a predictor for mortality, again except for those participants with a blood 
pressure lower than 140/70 mmHg. Our finding supports the general clinical 
feeling that at old age a blood pressure lower than 140/70 mmHg is relatively 
rare; in the present cohort only 8.4 % of the participants had blood pressures lower 
than 140/70 mmHg. This is in sharp contrast to younger age groups where these 
ranges of blood pressures are considered to be normal. The finding that blood 
pressures higher than 140/70 mmHg are found not to be associated with mortality 
risk in the oldest old might have important clinical implications. Moreover, a blood 
pressure below 140/70 mmHg in the general population of oldest old identifies 
a new high-risk subgroup. The therapeutic consequences of these findings are 
unknown and have to be explored in future. The fact that a history of hypertension 
remains a risk factor for cardiovascular mortality in old age, independent of the 
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High blood pressure is associated with decline of renal function. Whether this is 
true for very old people largely is unknown. Therefore, the study assessed the 
effect of blood pressure on creatinine clearance over time in very old participants. 
A total of 550 inhabitants (34% men) of Leiden, The Netherlands, were enrolled 
in a population-based study at their 85th birthday and followed until death or age 
90. Blood pressure was measured twice at baseline and at age 90 years. Creatinine 
clearance was estimated annually (Cockcroft-Gault formula). The mean creatinine 
clearance at baseline was 45.4 ml/min (SD 11.5). Systolic blood pressure was not 
associated with changes in creatinine clearance during follow-up. Those with 
diastolic blood pressure below 70 mmHg had an accelerated decline of creatinine 
clearance (1.63 ml/min/year) compared with those with diastolic blood pressures 
between 70 and 79 mmHg (1.21 ml/min/year; P = 0.01), 80 to 89 mmHg (1.26 
ml/min/year; P = 0.03), and higher than 89 mmHg (1.38 ml/min/year; P = 0.32). 
Participants with a decline in systolic blood pressure during follow-up had an 
accelerated decline of creatinine clearance compared with yhose with stable blood 
pressures (1.54 ml/min/year [SE 0.09] versus 0.98 ml/min/year [SE 0.09]; P < 
0.001). Similar results were found for a decline in diastolic blood pressure (1.54 
ml/min/year [SE 0.10] versus 1.06 ml/min/year [SE 0.08]; P < 0.001). In the oldest 
individual, high blood pressure is not associated with renal function. In contrast, 
low diastolic blood pressure is associated with an accelerated decline of renal 
function. The clinical implications of these findings have to be studied.




An old age, renal function will be compromised as a result of progressive loss of 
glomeruli and decline in renal blood flow [1], especially in those with persistent 
high blood pressure [2]. Because blood pressure increases with age, this implicates 
a possible double strike for creatinine clearance in the oldest individual [3].
In contrast with younger populations, in the oldest individuals, the association 
among high blood pressure, mortality and renal function is not straightforward. 
The available data suggest that blood pressure lowering above 80 years does not 
lower overall mortality [4,5]. Data on the effect of blood pressure on morbidity 
such as renal function are relatively scarce in the oldest individuals [6-8]. One 
longitudinal report associated blood pressure and renal function in a considerable 
group of very old Japanese individuals [7]. In that report, high blood pressure 
was related to an excess decline of serum creatinine. However, an important 
drawback was the use of serum creatinine for estimation of renal function. In 
addition, selection bias could have been induced as a result of exclusion of 40% of 
the participants, who did not attend the reexamination after 3 years. 
Although blood pressure lowering in individuals over 80 years might not lower 
mortality, it is unknown if a high blood pressure might be deleterious for renal 
function. To investigate whether high blood pressure still is a risk factor for decline 
in renal function in the oldest individuals, we prospectively studied the effect of 
blood pressure on changes of creatinine clearance over time in a population-based 





The Leiden 85-plus Study is a prospective population-based study of all 85-year-
old inhabitants of Leiden, The Netherlands. The study design and characteristics of 
the cohort were described in detail previously [9,10]. In short, between September 
1997 and September 1999 all 705 members of the 1912 to 1914-birth cohort in the 
city of Leiden were asked to participate in the month after their 85th birthday. 
There were no selection criteria related to health or demographic characteristics. 
Participants were followed until death or the age of 90. At baseline and yearly 
thereafter, 85-year-old participants were visited at their place of residence. During 
these visits, participants were weighed, blood pressure was measured, a venous 
blood sample was drawn, an electrocardiogram was recorded and face-to-face 
interviews and performance tests were conducted. Information on the medical 
history was obtained by standardized interviews of the participant’s treating 
physicians. In addition, information on the use of medication was obtained from 
the participant’s pharmacist. Participants gave informed consent; for people 
who were severely cognitively impaired, a guardian gave informed consent. The 
Medical Ethics Commission of Leiden University approved the study.
Blood pressure 
At baseline and at age 90 years, blood pressure was measured twice, with a mean 
intervening period of 2 weeks. Blood pressure was measured, using a mercury 
sphygmomanometer, in the seated position after at least 5 min of rest and no 
vigorous exercise the preceding 30 min. The systolic value was measured at 
Korotkoff sound 1, and the diastolic value was measured at Korotkoff sound 5. 
For the analysis of blood pressure, we used the mean of the measured systolic 
and diastolic values. For the analysis of pulse pressure, we used the mean systolic 
minus the mean diastolic blood pressure. Data are presented according to four 
strata of systolic blood pressure (<140, 140 to149, 150 to 159, and ≥ 160 mmHg), 
four strata of diastolic blood pressure (<70, 70 to 79, 80 to 89, and ≥ 90 mmHg), and 
quartiles of pulse pressure. The change of systolic and diastolic blood pressure 
between ages 85 and 90 was categorized into 3 groups: Declining (≥ 10-mmHg 
decrease), stable (<10-mmHg increase or <10-mmHg decrease) and increasing (≥ 
10-mmHg).




At entry and at yearly intervals thereafter, both the serum creatinine concentration 
and bodyweight were measured. Creatinine was fully automatically measured 
according to the Jaffé method (Hitachi 747; Hitachi, Tokyo, Japan). The creatinine 
clearances were estimated yearly with the Cockcroft-Gault formula as follows [11]: 
(140 – Age) x weight (kg) x 1.23 
Creatinine clearance =     x (0.85 if female) 
   serum creatinine (μmol/l)
Demographic and clinical characteristics
At baseline, a research nurse collected information concerning the demographic 
characteristics. The presence of cardiovascular disease was defined as a previous 
history of cerebrovascular accident, angina pectoris, myocardial infarction, 
peripheral vascular disease (including a history of arterial grafting, endarterectomy 
and angioplasty) or an electrocardiogram revealing myocardial ischemia or 
infarction (Minnesota codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-2 and 5-3) [12]. The 
presence of chronic disease was defined as a history of diabetes, Parkinson’s 
disease, chronic obstructive pulmonary disease, osteoarthritis, or malignancies. 
Antihypertensive drugs were classified as usage of angiotensin converting 
enzyme inhibitor, angiotensin-1 receptor blocker, thiazid diuretic, dihydropyridin 
calcium channel blocker or β-blocker with the exclusion of Sotacor. We had data 
on use of anti-hypertensive medication at the ages of 85 and 86.
Statistical analyses
Data were presented as percentages for clinical characteristics and as the mean with 
standard deviation for continuous variables. The differences in mean creatinine 
clearances between the categories of blood pressure at baseline were compared 
with independent t test. The associations over time between creatinine clearance 
(ml/min) and categories of diastolic and systolic blood pressure were analyzed 
with a linear mixed model. The creatinine clearance was the dependent factor. 
The outcome was the effect on the change in creatinine clearance of the interaction 
between time and categories of blood pressure. This analysis models the change 
over time by computing the rate of change for each participant on the basis of 
all data for that individual adjusted for gender and other possible confounders. 
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Then the rate of changes for the entire group and the individual deviation from 
the group rate are computed. This model analyzes the unique effects of individual 
predictors adjusted for all other fixed and random predictors, accounts for 
the correlation among repeated measurements on the same participant, and is 
unaffected by randomly missing data. To investigate the effects of missing data 
due to mortality, we repeated all analyses with exclusion of participants who died 
within the first year of follow-up and repeated all analyses with inclusion only of 
surviving participants who participated up to age 90 years. 
An additional analysis was done to examine the effect of a decline in systolic 
and diastolic blood pressure between ages 85 and 90 on the decline of creatinine 
clearance in participants who were alive at age 90. The associations between the 
groups of blood pressure and creatinine clearance were analyzed with a linear 
mixed model. All analyses were done with software SPSS version 12.0 (SPSS, Inc. 
Chicago, IL).
Results
Of the 705 eligible participants, 14 died before they could be enrolled and 92 refused 
to participate, resulting in a cohort of 599 participants (87 % response). Only one 
blood pressure measurement was available for 27 participants, serum creatinine 
at baseline was missing in 11 participants and body weight in 11 participants. 
Thus, in these analyses we included 550 participants (Table 1). During follow up, 
34 participants declined further participation and 243 participants died (Figure 
1). At age 86, 36 participants had started antihypertensive medication and 54 
had stopped antihypertensive medication. There were no significant associations 
between the categories of diastolic and systolic blood pressure and changes of use 
of antihypertensive medication between ages 85 and 86 years (data not shown).
Blood pressure and creatinine clearance at old age.
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Table 1: Baseline characteristics of 550 participants aged 85 years.
Females 363 (66%)
History of hypertension 218 (40%)
Antihypertensive treatment 201 (37%)
Mean diastolic blood pressure (mmHg [SD]) 76.9 (9.4)
Mean systolic blood pressure (mmHg [SD]) 155.6 (18.4)
Mean pulse pressure (mmHg [SD]) 78.7 (15.2)




No history of chronic diseasesb 227 (41%)
Diagnosis of diabetes 87 (16%)
a Including history of peripheral vascular disease, cerebrovascular accident, angina pectoris, 
myocardial infarction, or an electrocardiogram revealing myocardial ischemia or infarction,
b History of diabetes, Parkinson’s disease, chronic obstructive pulmonary disease, 
osteoarthritis, or malignancies.





















At baseline the mean creatinine clearance was 45.4 ml/min (standard deviation 
[SD] 11.5 ml/min). Females had a 2.19 ml/min (standard error [SE] 1.04 ml/min) 
lower creatinine clearance compared with men (P < 0.035). During follow-up, 
the overall decline in creatinine clearance was 1.31 ml/min per year (SE 0.06, P 
< 0.001). At baseline, four participants had end-stage renal failure, defined as a 
creatinine clearance less than 15 ml/min. During follow-up, three participants 
progressed to end-stage renal failure: Two at age 89 years and one at age 90 years.
At baseline, creatinine clearance was correlated with the presence of cardiovascular 
disease. For every additional cardiovascular disease, creatinine clearance was 
2.05 ml/min (SE=0.54, P < 0.001) lower. During follow-up, creatinine clearance 
declined with an extra 0.21 ml/min per year (SE 0.07, P = 0.002) over the normal 
annual decline for every additional manifestation of cardiovascular disease. A 
history of hypertension and diabetes (Table 2) was not associated with the decline 
of renal function either at baseline or during follow-up.
At baseline, creatinine clearance was not dependent on systolic blood pressure or 
pulse pressure (all comparisons between groups, P > 0.18). In contrast, diastolic 
blood pressure at baseline was significantly associated with creatinine clearance: 
Creatinine clearances were significantly lower in the two lowest categories (<70 
and 70 to 79 mmHg) of diastolic blood pressure (43.8 ml/min [SE 0.98], 44.7 
ml/min [SE 0.77]) compared with the two highest categories (80 to 89 and ≥90 
mmHg) of diastolic blood pressure (47.5 ml/min [SE 0.97], 46.5 ml/min [SE 1.61]; 
P = 0.005). The associations among systolic, diastolic blood pressure and pulse 
pressure versus creatinine clearance were similar in men and women (data not 
shown). 
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Table 2: Additional change in creatinine clearance (ml/min) per year during follow-up 
until death or the age of 90, according to the number of cardiovascular diseases, the 
history of hypertension, and the history of diabetes at baseline in 550 participantsa.
Crude model Adjusted model
ml/min (SE) P-value ml/min (SE) P-value
Number of cardiovascular diseasesb - 0.21 (0.07) 0.002 - 0.21 (0.07) 0.002
History of hypertensionc -0.12 (0.12) 0.31 -0.12 (0.12) 0.30
History of diabetes mellitusc -0.18 (0.17) 0.27 -0.18 (0.17) 0.27
aAnalyses with linear mixed model with estimates plus Standard Errors (SE) of the mean. 
Crude model: adjusted for gender. Adjusted model: adjusted for gender and use of 
antihypertensive medication at age 85 and 86. 
bChange per additional number (range: 0 to 5) of cardiovascular diseases present. 
cChange according to positive history versus negative history of hypertension and diabetes.
Relations between baseline blood pressure and changes in renal function over 
time were similar to those observed at the cross-sectional analyses. There was 
no association between baseline systolic blood pressure or pulse pressure 
and the annual decline of creatinine clearance (Figure 2). However, baseline 
diastolic blood pressure lower than 70 mmHg was associated with a significantly 
accelerated decline of creatinine clearance during follow-up when compared 
to higher diastolic blood pressures (Figure 2). These findings remained similar 
after exclusion of 42 participants who died within the first year of follow-up. 
The restricted analyses for 273 surviving participants who participated up to 90 
years did also not change the significant association between low diastolic blood 
pressure and an accelerated decline of creatinine clearance. The yearly decline in 
creatinine clearance was –1.58 ml/min for 53 participants with baseline diastolic 
blood pressure < 70 mmHg (reference group), -1.13 for 70 to 79 mmHg (n = 112, 
P = 0.006), -1.13 for 80 to 89 mmHg (n = 82, P = 0.01), and –1.30 (n = 26, P = 0.24) 
for > 89 mmHg. 
During follow-up a low diastolic blood pressure was consistently associated with 
an accelerated decline of creatinine clearance in those with and those without 
cardiovascular disease at baseline (data not shown). Stratification according to the 
median of creatinine clearance at baseline did not reveal a different effect of blood 
pressure on creatinine clearance over time (data not shown).
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Figure 2. Yearly decline of creatinine clearance depending on categories of blood 
pressure and pulse pressure. Analyses with linear mixed model with estimates plus 
standard errors of the mean. Adjusted for gender, cardiovascular disease, chronic 
disease and use of antihypertensive medication at age 85 and 86 year. Diastolic blood 
pressure was adjusted for systolic blood pressure and vice versa. P-values reflecting 
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Figure 3 presents the annual decline of creatinine clearance in survivors up to 90 
year according to the change of blood pressure from age 85 up to 90. Those with a 
decline in systolic blood pressure had an accelerated decline of creatinine clearance 
-from age 85 up to 90- compared with those with a stable systolic blood pressure 
(1.54 ml/min/year [SE 0.09] versus 0.98 ml/min/year [SE 0.09]; P < 0.001). Those 
with a decline in diastolic blood pressure had an accelerated decline of creatinine 
clearance –from age 85 up to 90- compared with those with a stable diastolic blood 
pressure also (1.54 ml/min/year [SE 0.10] versus 1.07 ml/min/year [SE 0.08]; P 
< 0.001). There were no associations between the presence of chronic disease, 
cardiovascular disease, history of hypertension or usage of antihypertensive 
medication at baseline and a decline versus an increase in systolic or diastolic 
blood pressure between 85 and 90 year (data not shown).
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Figure 3: Annual decline of creatinine clearance in 273 survivors up to 90 year depending 
on a decline, stable or increase in systolic and diastolic blood pressure in-between age 
85 to age 90. Analyses with linear mixed model with estimates plus standard errors of 
the mean. Adjusted for gender and use of antihypertensive medication at age 85 and 
86. P-values reflecting the differences in additional annual decline compared to the 







































































































































































In our prospective, population based study of the oldest individuals, we found 
no association between high systolic blood pressure and decline of creatinine 
clearance during follow-up. Strikingly, a diastolic blood pressure below 70 
mmHg preceded an accelerated decline of creatinine clearance during follow-up. 
Moreover, a decline in systolic and diastolic blood pressure from ages 85 up to 90 
was related to an accelerated decline of creatinine clearance.
In younger age groups, the deleterious effect of elevated diastolic and systolic 
blood pressure on renal function is beyond doubt [13]. Up to an average age of 72 
year, harmful effects of systolic blood pressure on renal function has been reported 
[14]. Intervention trials have shown that blood pressure lowering prevents renal 
failure, independently of renal function at baseline [15]. Therefore, it is surprising 
that we could not find an association between elevated blood pressure (diastolic 
and systolic) and creatinine clearance in our elderly participants. To date, only one 
published longitudinal study with a considerable amount of very old participants 
has shown that high blood pressure was associated with a decline of creatinine 
clearance [7]. However, renal function was estimated with two measurements of 
serum creatinine three years apart. In older people, serum creatinine is less reliable 
as an estimate for renal function due to progressive loss of muscle mass [1,16]. In 
addition, only 60% of the participants who attended the first examination were 
reexamined after three years, possibly inducing selection bias. We did find an 
annual decline of renal function of 1.3 ml/min/year and also gender differences 
in creatinine clearances, both in line with the literature [17-20]. In addition, a 
strong association with cardiovascular disease and creatinine clearance existed 
at baseline and during follow-up [21]. Therefore, we do think that our data are 
reliable and representative for the oldest individuals. 
How can we explain the effect of a low diastolic blood pressure on creatinine 
clearance over time and the accelerated decline in creatinine clearance that is 
associated with a decline in blood pressure? Possibly, a low diastolic blood 
pressure in the ninth decade is a reflection of a decline in blood pressure in the 
years before. The underlying mechanism of the accelerated decline of creatinine 
clearance might be chronic hypoperfusion of the kidneys. The vulnerability of the 
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kidney in the elderly could be related due to an impaired autoregulatory response 
of the renal arteries in the presence of atherosclerosis.
Different from in middle age, high blood pressure in elderly has been associated with 
an increased, equal, or even decreased mortality [22-24]. Within our prospective 
cohort study, high blood pressure was not related to an increased mortality risk 
after age 85 years [25]. In addition, it is not established whether hypertension 
should be treated in the very old. A meta-analysis of treated participants of 80 
years and older included in hypertension trials had inconsistent results [5]. A 
placebo-controlled trial for treatment of hypertension in people above 80 year is 
still running [26]. The pilot study did not show a survival benefit for treatment; 
even worse, a non-significant trend towards excess mortality was found in the 
treated group [4]. However, some beneficial effect was seen on the reduction of 
strokes. Given these considerations, our finding that an elevated blood pressure is 
not a risk factor for decline of renal function in the oldest old is of interest.  
Because our data are from a prospective population-based study with a high 
response rate and virtually no dropouts during follow-up, we were able to observe 
the impact of blood pressure on renal function of the oldest individuals in the 
population at large. Another strength is that we measured blood pressure twice 
and assessed the creatinine clearance yearly for a period of 5 years. Although the 
estimation of creatinine clearance with the Cockcroft-Gault formula is not the 
gold standard to measure renal function, this is a very widely used and validated 
method for estimation of the creatinine clearance [11,16,17,19]. Because we did not 
have reliable data on clinical heart failure, this might have influenced our results. 
The linear mixed model that was used is an accurate model that can handle at 
random missing data. Participants who die probably will not die at random. 
However, our results remained similar in the additional analyses without the 
participants who died within the first year and also in the restricted analyses for 
survivors up to age 90 years. These additional analyses show that our results are 
unlikely to be influenced by underlying survivor bias. 
In contrast with younger age groups, elevated systolic and diastolic blood pressure 
did not influence the annual decline in renal function in the oldest individuals. A 
diastolic blood pressure lower than 70 mmHg and a decline in systolic or diastolic 
Blood pressure and creatinine clearance at old age.
53
3
blood pressure between ages 85 and 90 was related to an accelerated decline of 
creatinine clearance over time. Clinical implications of these findings have to be 
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To determine the prospective relationship between blood pressure (BP) and 
cognitive function across a wide age range.
Design:
Prospective population-based cohort study.
Setting:
The Rotterdam Study and the Leiden 85-plus Study.
Participants:
Three thousand seventy-eight men and women, initial age 55 to 84 from the 
Rotterdam Study and 276 men and women, initial age 85, from the Leiden 85-plus 
Study.
Measurements:
Systolic BP (SBP) and diastolic BP (DBP) were measured at baseline, cognitive 
function was assessed at the end of follow-up using a dedicated neuropsychological 
test battery. The association between baseline BP levels and cognitive function 
later in life was assessed in 10-year age groups in the Rotterdam Study and in 
85-year-olds of the Leiden 85-plus Study.
Results:
In the youngest participants (<65), SBP and DBP were not associated with cognitive 
function 11 years later. For persons aged 65 to 74, higher baseline SBP and DBP 
were related to worse cognitive function 11 years later. In contrast, in older age 
(≥75), higher SBP and DBP seemed to be related to better cognitive function at 
the end of follow-up. This effect appeared strongest in the highest age group (85 
years).
Conclusion:
High BP was associated with greater risk of cognitive impairment in persons 
younger than 75 but with better cognitive function in older persons. Age-specific 
guidelines for BP management are needed, because the current directive that 
“lower is better” may not apply to BP levels in the very old.




Data on the relationship between BP and cognitive function are not consistent, 
notwithstanding a large number of studies that have investigated the relationship.
[1] Most studies report that higher BP levels at middle age relate to cognitive 
impairment later in life,[2–5] but results on the relationship between higher BP in 
older age and later cognitive function are conflicting. Some studies have shown a 
negative effect of higher BP on cognitive function,[6,7] whereas others have not.
[8,9] These findings may suggest that age influences the relationship between BP 
and cognitive function. If this suggestion is correct, it might have consequences 
for BP management, especially in very old people. Earlier evidence of beneficial 
effects of BP lowering on cognitive function in older people[10] could not be 
replicated in recent studies,[11] despite the fact that stroke risk was significantly 
lower in those studies. Therefore, the effect of age on the relationship between 
baseline BP and cognitive function later in life was examined over a wide range 
of age groups in two prospective population-based studies (the Rotterdam Study 
and the Leiden 85-plus Study). It was hypothesized that the relationship between 
BP and cognitive function changes with age. Whereas high BP is a risk factor for 
cognitive impairment at middle age, it might have beneficial effects in old age.
Methods
Populations
The Rotterdam Study is a large, prospective, population-based cohort study 
conducted in all inhabitants aged 55 and older of Ommoord, a district of 
Rotterdam, The Netherlands.[12] The medical ethics committee of the Erasmus 
University of Rotterdam approved the study, and informed consent was obtained 
from all participants. Of 10,275 eligible subjects, 7,983 (77.7%) participated in the 
baseline examinations between 1990 and 1993 (mean age 71.2±25.2, range 55–106). 
All participants were interviewed at home and visited the research center for 
further examinations. At the fourth survey (2002–2004), cognitive function was 
extensively assessed using a dedicated neuropsychological test battery.
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The Leiden 85-plus Study is a prospective population-based cohort study of 
85-year-old inhabitants of Leiden, The Netherlands. The medical ethics committee 
of the Leiden University Medical Centre approved the study, and informed consent 
was obtained from all participants. Between September 1997 and September 1999, 
all 705 inhabitants of Leiden born between 1912 and 1914 were contacted within a 
month after their 85th birthday; 599 (85.07%) agreed to participate. From age 85 to 
90, annual neuropsychological tests were performed during home visits.
Study Sample
In the Rotterdam Study, the sample for this study was restricted to the 6,502 
participants aged 55 to 85 with BP measurements at baseline because of the 
limited number of participants aged 85 and older with follow-up examinations 
11 years later (n=4). Of these 6,502 participants, 3,424 (52.7%) did not participate 
in the fourth survey; 63.7% had died, 29.4% refused the in-person examination 
or were too ill to visit the research center, and 6.9% could not be contacted. The 
proportion of participants who did not participate in the fourth survey increased 
with age, from 30.9% for age 55 to 64 to 54.4% for age 65 to 74 to 87.8% for age 75 
to 84. The study sample therefore consisted of 3,078 participants with baseline BP 
measurements and cognitive measurements 11 years later.
In the Leiden 85-plus Study, BP was measured in 572 participants at age 85; 276 
of these underwent neuropsychological testing 5 years later at age 90. Of the 
remaining 296 individuals (51.7%) who did not participate at age 90, 87.5% had 
died, and 12.5% refused to participate.
Blood Pressure
In both study samples, systolic BP (SBP) and diastolic BP (DBP) were measured 
twice at baseline using a sphygmomanometer after 5 minutes of seated rest. The 
averages of two measurements were used in the analyses. In the Rotterdam Study, 
the two measurements were separated by a count of the pulse rate. In the Leiden 
85-plus Study the two measurements were 2 weeks apart.
Cognitive Function
Global cognitive function was measured in both cohorts using the Mini-Mental 
State Examination (MMSE; range 0–30, lower scores indicating worse cognitive 
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function).[13] Only a serial 7s question was used, not the WORLD-backward 
version. In addition, a dedicated neuropsychological test battery was used to 
assess executive function and memory. Executive function was assessed using the 
abbreviated Stroop Test part 3[14] and the Letter Digit Substitution Task (LDST)
[15] in both cohorts and the Word Fluency Test (WFT)[16] in the Rotterdam Study 
only. Memory was assessed using the 15-Word Learning Test (15-WLT) immediate 
and delayed recall[17] in the Rotterdam Study and the 12-Picture Learning Test 
(12-PLT) immediate and delayed recall[18] in the Leiden 85-plus Study. Dutch-
translated and -validated versions were used for all neuropsychological tests.
MMSE score was used as a measure of global cognitive function. In the Leiden 85-
plus Study, executive function and memory were not assessed in participants with 
a MMSE score of 18 points or lower (n=74) because it was assumed that the tests 
lack reliability and validity in subjects with severe cognitive impairment. These 
participants were assigned to the lowest quartile of the distribution to reflect their 
impaired state of cognitive function.
Additional Measurements
In both study populations, education was measured at baseline and dichotomized 
into primary education or less versus more than primary education. 
Antihypertensive drug use was determined at baseline during the home interview 
(Rotterdam Study) or through pharmacy records (Leiden 85-plus). Smoking 
status, alcohol intake, history of stroke, history of diabetes mellitus, and history of 
cardiovascular disease were assessed at baseline.
Statistical Analysis
The association between baseline BP and cognitive function later in life was 
examined using linear regression models, with BP as independent and cognitive 
test score as dependent variable. All analyses were adjusted for age (Rotterdam 
Study only), sex, and education level. Additional adjustments were made for the 
use of antihypertensive drugs, smoking status, alcohol intake, history of stroke, 
history of diabetes mellitus, and history of cardiovascular disease. Analyses were 




Table 1 shows the baseline characteristics of participants who did and did not 
undergo cognitive testing at the follow-up examination for both cohorts. In both 
studies, the percentage of women was higher, and their proportion increased 
with age. The level of education was lower in older age (in those who originated 
from earlier birth cohorts). Average SBP increased and DBP decreased with age, 
although DBP was highest in the oldest old. The percentage of participants with a 
history of stroke, diabetes mellitus, or cardiovascular disease increased with age, 
as did the use of antihypertensive treatment.
In the Rotterdam Study, participants without cognitive assessment at follow-up 
were older and less educated and had higher SBP and DBP and worse cognitive 
function at baseline than the participants included in the analyses. This was seen 
similarly for all age groups from age 55 to 85. In the oldest old (Leiden 85-plus 
Study), participants who did not undergo cognitive testing at the follow-up 
examination had lower SBP and DBP and concurrent worse cognitive function 
at baseline than the participants included in the analyses. In both samples, 
participants who were not included in the analyses more often had a history of 
stroke, diabetes mellitus, or cardiovascular disease than participants in the study 
samples.
Figure 1 shows the effect of age on the association between baseline BP and 
cognitive function later in life. Individuals up to 65 years of age showed in 
general little decline in cognitive function over the 11-year follow-up period, and 
neither baseline SBP nor DBP was related to cognitive function 11 years later. 
In individuals aged 65 to 74, higher SBP and DBP at baseline were related to 
worse cognitive function 11 years later. With older baseline age, the effect of BP 
on cognitive function seemed to invert; in individuals aged 75 and older, higher 
SBP and DBP at baseline were related to better cognitive function 11 years later, 
although in the Rotterdam Study, the number of people in this age group was 
small, and consequently results were not significant for the majority of tests. 
This effect was even stronger in the highest age group (85 years, subjects from 
the Leiden 85-plus Study), with higher SBP and DBP related to better cognitive 
function 5 years later. The shift from risk to benefit of high BP from age 65 to 85 
years was observed for all neuropsychological tests (Figure 1).















































































































































































































































































































































































































































































































































































































































































































































Figure 1. The effect of age on the association of baseline blood pressure and cognitive 
function later in life. Symbols represent the mean standardized cognitive test scores 
and 95% confidence intervals per 10 mmHg increase in systolic (A) and diastolic (B) 
blood pressure. For graphical reasons, the estimates for the Stroop test were inversed 
because a higher Stroop score reflects worse cognitive function. Analyses were adjusted 
for age (Rotterdam Study only), sex and level of education.
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Additional adjustments for the use of antihypertensive drugs, smoking status, 
alcohol intake, history of stroke, history of diabetes mellitus, or history of 
cardiovascular disease did not markedly change any of these results (data not 
shown).
Discussion
These data show that age has an important effect on the relationship between 
BP and cognitive function later in life. In participants younger than 75, higher 
SBP and DBP were associated with worse cognitive function 11 years later. This 
relationship reversed in older participants, in whom higher SBP and DBP at 
baseline were associated with better cognitive function later in life.
The detrimental effect of higher BP levels on cognitive performance in middle-
aged people is well established,[2–5] and the results from the analyses in the 
65- to 74-year age group in the Rotterdam Study sample were consistent with 
these previous findings. The mechanisms behind this association may involve 
atherosclerotic changes in large and hyaline degeneration in small cerebral 
vessels, ischemic brain lesions, and disturbances in endothelial or brain cell 
permeability,[1–5] although in the oldest-old participants in the Rotterdam Study, 
high BP at baseline was related to better cognitive function later in life, and when 
the analyses were replicated in the 85-year-old participants of the Leiden 85-plus 
Study sample, similar results were found.
In the current study, participants with low BP and good cognitive function at 
baseline were more likely to be included in the study sample than participants 
with higher BP and worse cognitive function at baseline. One might expect 
that this selective attrition could have influenced the results, especially in the 
oldest age group of the Rotterdam Study, in which a large proportion (87.8%) of 
the participants who were present at baseline were not available at follow-up. 
Although selective attrition may have attributed to the formation of a selective 
group of survivors in the oldest age group of the Rotterdam Study, this does 
not necessarily diminish the importance of the findings that, in this group of 
individuals, high BP was related to better cognitive function later in life.
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The results on the relationship between BP and cognitive function from the Leiden 
85-plus Study, with data available on the oldest old (aged 85 years), confirmed 
those from the Rotterdam Study. Although the proportion of participants in the 
Leiden 85-plus sample who were not available at follow-up was also considerable 
(51.72%), these participants had predominantly lower BP levels and worse 
cognitive function than those included in the analyses. This concurs with previous 
findings that high BP is not a risk factor for mortality in the oldest old.[19,20]
Although the observations cannot be interpreted that BP management should be 
changed in old individuals, they underscore the need for further elucidation of 
risks and benefits of BP lowering therapy in the oldest old.
The previous studies that associated higher BP in middle-age with worse 
cognitive function later in life[2–5] suggested that antihypertensive treatment 
might prevent or delay the onset of impaired cognitive function, but data from 
randomized clinical trials on the beneficial effects of antihypertensive treatment 
on cognitive function are not consistent.[7,10,21–23] From these earlier studies, 
only the Syst-Eur trial,[10] which studied the effect of treatment with nitrendipine 
with the possible addition of enalapril and hydrochlorothiazide on incidence of 
dementia, showed benefit that could not be replicated in the Hypertension in the 
Very Elderly Trial (HYVET).[11] This large, double-blind, placebo-controlled trial 
included 3,336 participants aged 80 and older and showed that antihypertensive 
treatment with indapamide with the option of perindopril did not reduce incidence 
of dementia.[11] Although the short follow-up, owing to the early termination of 
the trial, could have affected this result, the alternative explanation is that there 
is no clear benefit in correspondence with the observational data presented here. 
Alternatively, the use of the relatively insensitive Mini-Mental State Examination 
as an outcome measure for cognitive impairment or decline could also have 
contributed to the inconsistent findings in clinical trials. Another explanation is 
that the oldest old in whom impaired cognitive function is most prevalent were 
underrepresented in these studies.
It is tempting to speculate why BP lowering is consistently associated with a 
lower risk of stroke, whereas this benefit is not reflected in consistent preservation 
of cognitive function. Although counterintuitive, the aggregated data from the 
observational and experimental studies suggest that, in the oldest old, higher BP 
may have also have a benefit with respect to cognitive function, possibly through 
The association of blood pressure with cognitive function.
67
4
the necessity of maintaining adequate cerebral perfusion.[24–26] Local regulation 
of cerebral blood flow tightly regulates cerebral perfusion over a wide range of 
BP.[27] A combination of myogenic and neurogenic mechanisms mediates this 
autoregulation of cerebral blood flow.[28] With older age, basal cerebral blood 
flow decreases, possibly caused by impaired cerebral autoregulation through 
atherosclerosis or endothelial dysfunction.[29,30] In the oldest old, higher BP may 
therefore be required to prevent cerebral hypoperfusion and preserve cognitive 
function. Individuals with greater risk of morbidity and mortality are present 
in the population-based prospective studies but are less likely to be included in 
randomized clinical trials. Participants of the HYVET[11] who were randomized 
to placebo had a mortality risk less than half that of the general population, 
indicating the recruitment of relative healthy people into the trial.
The current study had several strengths. Data on BP and cognitive function were 
available from two independent Dutch prospective population-based studies. 
These two cohorts are complementary and allowed the association between BP 
level and cognitive function from age 55 onward to be examined. The dedicated 
neuropsychological test batteries that were used in both studies were comparable 
and assessed several cognitive domains, including global cognitive function, 
executive function, and memory. Some of the participants in the oldest age 
group (Leiden 85-plus Study) could not undergo all the cognitive tests that were 
available because of their severely impaired cognitive status (MMSE score≤18). 
Rather then excluding these persons from the analyses, the information on the 
cognitive status of these participants that was available (MMSE score) was used 
to infer their scores on the other cognitive tests.
There were also some limitations. The associations between BP and cognitive 
function were based on the assessment of BP at baseline and the measurement of 
cognitive function 11 years (Rotterdam Study) or 5 years (Leiden 85-plus Study) 
later. The difference in follow-up length between the two study samples warrants 
some caution in the comparison and interpretation of the results, because the 
Rotterdam Study results are based on 11 years of follow-up, compared with 5 
years of follow-up in the Leiden 85-plus Study. Despite the long follow-up 
periods, extension of these periods may have revealed even stronger associations 
between baseline BP and cognitive function later in life, because the effect of BP on 
cognitive function is thought to be long-term.[1] This may especially play a role 
up to the age of 65, for which the follow-up period may just have been too short. 
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However, a longer follow-up, especially in older age, would also lead to further 
dropout of participants and consequently to limited statistical power, as well as 
the potential of survival bias.
In conclusion, this study shows that the relationship between baseline BP levels 
and cognitive function later in life differs across age groups. Although there is not 
a clear age cut-off at which the relationship between BP and cognitive function 
later in life inverses, there seems to be a gradual shift with age from high BP being 
a risk factor for cognitive impairment to high BP potentially helping to preserve 
cognitive function in the oldest old, presumably through maintaining perfusion 
pressure. The data illustrate that it should not simply be assumed that advice 
to 65-year-olds on target BP should be the same as advice to 85-year-olds and 
underscore the need for further elucidation of risks and benefits of BP lowering 
therapy in the oldest old.
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Low blood pressure in the very old has been associated with organ dysfunction 
and excess mortality but the underlying mechanism has yet to be elucidated. We 
hypothesized that cardiac dysfunction contributes to low blood pressure in the 
very old. We invited a convenience sample consisting of 82 participants all aged 
90 years from a population based cohort study in the very old. Blood pressure 
was measured twice and all but one underwent echocardiography to assess 
cardiac dimensions and functional cardiac parameters. Some 47 participants 
were free from hemodynamically significant valvular disease and were included 
in the present analyses. There were low values for mean cardiac output (2.04 l/
min/m2, SE 0.40) and mean stroke volume (31.4 ml/m2, SE 7.7). For every 10-
mmHg decrease in systolic blood pressure, cardiac output was 0.09 L/min/
m2 lower (SE 0.04, p=0.019) and stroke volume was1.58 ml/m2 lower (SE 0.68, 
p=0.024). Mean left ventricular ejection fraction was normal and 2.39% (SE 1.16, 
p=0.046) higher for each 10-mmHg decrease in systolic blood pressure. Mean left 
ventricular dimensions were normal but the E/A ratio was reduced (0.68, SD 
0.21), indicating diastolic dysfunction. In conclusion, among the oldest old, low 
systolic blood pressure correlates with low cardiac output. Systolic ventricular 
function is not impaired.




There is a wide range of observational data on the relation between blood pressure 
and mortality in the very elderly but the outcomes are not unanimous. [1-6]. Some 
of the studies have shown the expected correlation between high blood pressure 
and increased mortality risk [6]. Some, however, did not find these associations 
[2-4]. Moreover, others reported the mortality risk to be higher in those with a 
relatively low blood pressure [1,5, 7]. In line with these unexpected findings we 
have recently shown low blood pressure to be associated with organ failure, for 
example loss of renal function [8]. 
In general, both diastolic and systolic blood pressure gradually increases up 
to middle age. From the sixth decade onwards, in most people, diastolic blood 
pressure tends to decrease, whereas the systolic blood pressure further increases 
[9]. This increase in ‘pulse pressure’ is generally interpreted as a consequence of 
arterial stiffening. At very old age, however, systolic blood pressure eventually 
decreases again and it is this decline in systolic blood pressure that is associated 
with a worse prognosis [1, 10]. 
If low blood pressure at very old age was a reflection of cardiac dysfunction, 
the increased mortality risk in those with low blood pressure would be easier to 
understand. To evaluate whether cardiac dysfunction may in part underlie the 
lower blood pressure in the very old we performed a comprehensive transthoracic 
echocardiographic examination in a population-based sample of older people all 
aged 90 years. 
Material and Methods 
Study population
The Leiden 85-plus Study is a prospective population-based study of all 85-year 
old inhabitants of Leiden, The Netherlands. The study design and characteristics 
of the cohort were described in detail previously [11,12]. In short, between 
September 1997 and September 1999 all 705 members of the 1912 to 1914-birth 
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cohort in the city of Leiden were asked to participate in the month after their eighty-
fifth birthday. There were no selection criteria related to health or demographic 
characteristics. At baseline and yearly thereafter, the 85-year old participants were 
visited at their place of residence up to age 90 years. During these visits blood 
pressure was measured, a venous blood sample drawn, an electrocardiogram 
recorded and face-to-face interviews and performance tests conducted. At 90 
years of age, participants were invited for an echocardiographic examination. 
All participants in the study gave informed consent, and when people were 
severely cognitively impaired, a guardian provided informed consent. The 
Medical Ethics Commission of the Leiden University Medical Center approved 
the study.
Echocardiography
All patients were imaged in the left lateral decubitus position using a commercially 
available system (Vingmed system /Vivid Seven; General Electric-Vingmed, 
Milwaukee, WI, USA). Images were obtained using a 3.5-MHz transducer at a 
depth of 16 cm in the parasternal (standard long and short axis) and apical views 
(two- and four-chamber images, long-axis view). The left ventricular dimensions 
(end-systolic and end-diastolic diameter) were determined from parasternal 
M-mode acquisitions; fractional shortening and left ventricular ejection fraction 
were derived [13]. Left ventricular stroke volume (assessed from pulsed-wave 
Doppler flow through the left ventricular outflow tract times the cross-sectional 
area of the outflow tract) and cardiac output (stroke volume times heart rate) were 
calculated. Left ventricular dimensions, stroke volume and cardiac output were 
subsequently corrected for body surface area.
The mitral inflow (assessed by pulsed-Doppler echocardiography, with the 
sample placed at the tip of the mitral leaflets) was used to assess the peak velocity 
of the early rapid filling wave (E) and late filling wave (A); the E/A ratio was used 
as a marker of diastolic function. The presence and severity of mitral and aortic 
regurgitation were graded semi-quantitatively from colour-flow Doppler images 
obtained from the conventional parasternal long-axis, apical four-chamber and 
apical long-axis views [14-16]. To avoid the influence of significant valvular 
disease in the relations between echocardiographic measurements and blood 
pressure, participants with hemodynamically significant valvular disease were 
excluded from the analyses.




Blood pressure was measured twice with an interval of two weeks. Blood pressure 
was measured, using a mercury sphygmomanometer, in seating position after at 
least five minutes rest without having performed vigorous exercise during the 
preceding 30 minutes. The systolic value was measured at the onset of phase 1, 
and the diastolic value was measured at the onset of phase 5 of the Korotkoff 
sounds. For the analysis of blood pressure we used the mean of the assessed 
systolic values and diastolic values. 
Demographic and clinical characteristics
At baseline, a research nurse collected information concerning the demographic 
characteristics. The Mini-Mental State Examination (MMSE) was administered 
to screen for cognitive impairment [17]. Disability in basic activities of daily 
living (ADL) was assessed with the Groningen Activity Restriction Scale (GARS) 
[18]. The presence of cardiovascular disease was defined as a previous history 
of cerebrovascular accident, angina pectoris, myocardial infarction, peripheral 
vascular disease or an electrocardiogram revealing myocardial ischaemia or 
infarction (Minnesota codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-2 and 5-3) [19]. 
Statistical analysis
The clinical characteristics were presented with the mean and standard error for 
normal distributed, continuous variables and with the median and interquartile 
ranges for not normal distributed variables. Differences between participants 
were tested with the two-sided independent T-test, the Mann Whitney test 
and Chi-square test respectively. All associations between blood pressure and 
echocardiographic characteristics were analysed with linear regression and 





Our initial cohort consisted of 599 participants (87% response) at age 85 years. 
Some 257 participants survived up to age 90 years on 1 April 2004 and were in 
principle eligible for the study. The study nurse invited a convenience sample 
consisting of 82 participants. All but one underwent echocardiography. The 
clinical characteristics of the study cohort and the 176 participants who did not 
undergo echocardiography are shown in table 1. Participants who underwent 
echocardiography had better cognitive function (higher MMSE scores) and less 
disability (lower ADL scores). They also had a significant higher systolic blood 
pressure.
Table 1: Clinical characteristics of participants aged 90 years
Echocardiograpic examination
Yes [n=81] No [n=176] p value
Female subjects [%] 66.7 76.1 0.11*
MMSE (IQR) [points] † 28 (26-29) 22 (16-27) <0.001‡
ADL (IQR) [points] § 10 (9.0-13.5) 16.0 (10-24) <0.001‡
History of cardiovascular disease [%]║ 48.1 55.1 0.30*
DBP (SE) [mmHg] 72.9 (8.9) 71.1 (9.9) 0.16¶
SBP (SE) [mmHg] 154.7 (16.0) 150.0 (18.8) 0.04¶
SE, Standard Error. IQR, Inter Quartile Range. †, Mini Mental State Examination. §, Activities 
in Daily Living. ║, Including cerebrovascular accident, angina pectoris, myocardial 
infarction, peripheral vascular disease or an electrocardiogram revealing myocardial 
ischemia or infarction at age 85. ‡, *, Independent T-test. ‡, Mann Whitney test. ¶, Chi Square 
test. N, number of participants. DBP, Diastolic Blood Pressure. SBP, Systolic Blood Pressure. 
Cardiac parameters
Some 20 participants had hemodynamically significant valvular disease. Blood 
pressure, both systolic and diastolic was not different between subjects with 
and without hemodynamically significant valvular disease (all p>0.06). As 
functional parameters could not be assessed unequivocally: participants with 
hemodynamically significant valvular disease were excluded in the present 
analyses. An additional 14 participants were excluded because no reliable 
estimation of the left ventricular outflow could be assessed (not allowing for 
assessment of stroke volume). Table 2 shows the echocardiography findings of the 
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remaining 47 participants. The cardiac index (mean 2.04 L/min/m2, SE 0,40) and 
stroke volume index (mean 31,4 ml/m2, SE 7.7) were lower than considered normal 
[20,21]. Moreover, a low systolic blood pressure was significantly associated with 
lower stroke volume index. For every 10-mmHg lower systolic blood pressure, 
stroke volume index was 1.58 ml/m2 (SE 0.68, p=0.024) lower (Figure 1a). The 
mean left ventricular ejection fraction was 66.9% (SE 10.8%) and for every 10-
mmHg decrease of systolic blood pressure, ejection fraction was 2.39% (SE 1.16, 
p=0.046) higher (Figure 1b). Similar but nonsignificant associations were observed 
between diastolic blood pressure and functional characteristics of the heart. For 
every 10-mmHg decrease in diastolic blood pressure, stroke volume index was 
1.54 ml/m2 (SE 1.22, p=0.21) lower whereas ejection fraction was 3.59% (SE 2.04, 
p=0.09) higher.
Left ventricular end-diastolic and end-systolic dimensions were within reference 
values [20,21]. The left ventricular end-diastolic diameter was above 2.8 cm/m2 
in 21 participants and four participants had a diameter beneath 2.0 cm/m2. The 
left ventricular end-systolic diameter was above 2.1 cm/m2 in five participants 
and beneath 1.3 cm/m2 in eight participants. The left ventricular dimensions 
were not related with diastolic or systolic blood pressure (all p>0.14). The average 
E/A ratio was low (mean 0.68, SE 0.22), indicating a high prevalence of diastolic 
dysfunction. However, the E/A ratio was not associated with systolic/diastolic 
blood pressure or cardiac output (all p>0.28).
Table 2: Echocardiograpic characteristics in 47 participants without hemodynamically 
significant valvular disease.
Mean (SE) Range Reference values
Cardiac Index [L/min/m2] 2.04 (0.40) 1.24-2.80 2.4-4.0
SV Index [ml/m2] 31.4 (7.7) 17.4-53.0 40-70
Heart rate [beats/min] 66.4 (10.8) 46-101
LVEF [%] 66.9 (12.8) 32-87
LVEDD Index [cm/m2] 2.73 (0.49) 1.86-3.86 2.0-2.8
LVESD Index [cm/m2] 1.70 (0.42) 0.58-2.59 1.3-2.1
E/A ratio 0.68 (0.21) 0.38-1.46
LVEF, Left Ventricular Ejection Fraction. LVEDD, Left Ventricular End Diastolic Dimension 
corrected for BSA (Body Surface Area). LVESD, Left Ventricular End Systolic Dimension 
corrected for BSA. SV, Stroke Volume. BP, Blood Pressure. SE, Standard Error.
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Figure 1: Cardiac performance dependent on systolic blood pressure.  
Analyses were done in 47 participants without hemodynamically significant valvular 














































































































































A low systolic and diastolic blood pressure was associated with a lower cardiac 
index. For every 10-mmHg lower systolic blood pressure, cardiac index was 0.09 
l/min/m2 (SE 0.04, p=0.019) lower. For every 10-mmHg lower diastolic blood 
pressure, cardiac index was 0.12 l/min/m2 (SE 0.06, p=0.06) lower. To study 
whether low blood pressure, which is associated with low stroke volume and low 
cardiac index, is appropriate on a systemic level, we have investigated the relation 
between stroke volume index and heart rate. Figure 2 displays that heart rates 
were significant higher in participants who had a lower stroke volume (p<0.001). 
Figure 2: Systemic response to cardiac performance.
Analyses form 47 participants without hemodynamically significant valvular disease 






































The main findings in our population-based study of nonagenarians consisted 
of fair evidence for an association between low systolic blood pressure and an 
impaired cardiac function. The cardiac index and the stroke volume index were 
on average below normal values and both were significantly and inversely related 
with systolic blood pressure. A low cardiac index and a low stroke volume index 
correlated with both, a low diastolic and a low systolic blood pressure. The left 
ventricular dimensions were mostly within normal values and were not related 
with diastolic or systolic blood pressure. Low blood pressure at very old age may 
thus reflect imminent heart failure, as defined by a diminished stroke volume 
and diminished cardiac output. It can be hypothesized that this association may, 
in part, underlies the association between low blood pressure and increased 
mortality [1,3-5].
There is only little data on routine echocardiograpic examinations in very old people 
[22, 23]. These studies have highlighted the presence of impaired left ventricular 
systolic function and the prevalence of left ventricular hypertrophy among the 
elderly. Another study analysed cardiac parameters of all clinically performed 
normal echocardiography examinations among persons who are 90 years and 
older but did not relate outcomes with clinical signs and symptoms [24]. Only 
one earlier publication made a link with blood pressure and echocardiography 
in community dwelling elderly [25]. No association was found between left 
ventricular ejection fraction and decrease of systolic and diastolic blood pressure. 
Measurements of cardiac index and stroke volume were not reported. As left 
ventricular hypertrophy did predict a decrease in blood pressure, these results 
suggest that diastolic dysfunction is involved in the process of decline in blood 
pressure in older age [25].
Pathophysiological reasoning implies that low blood pressure results from either 
a normal or high cardiac output with concomitant low peripheral resistance 
or from a low cardiac output with a high peripheral resistance. We were not 
informed about the peripheral resistance in our participants but we found 
low cardiac output to be associated with lower systolic blood pressure, that is 
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impaired cardiac performance. The first physiological adaptation to compensate 
for a low stroke volume is an increase in heart rate, consequent on stimulation of 
the sympathetic nervous system via the baro-receptor reflex [26]. It seems unlikely 
that the elevated heart rate among the study participants has been consequent 
on autonomous sympathetic activation as under such circumstances, concomitant 
blood pressure would have been higher also. Therefore we reason that among the 
oldest old, an elevated heart rate is likely to be a systemic adaptation of cardiac 
dysfunction. Previously, we have reported on this same cohort that a higher heart 
rate on annual repeated electrocardiograms was predictive of mortality [27]. The 
data presented here, higher heart rates reflecting a compensatory response to 
impaired cardiac function, are an alternative biological explanation of our report.
In our sample the average stroke volume index and the E/A ratio were low: 
the findings together indicate a high prevalence of diastolic dysfunction [28], 
especially as significant valvular lesions were excluded. Hence, older people may 
have a stiff left ventricle with an impaired diastolic filling, which in turn may give 
a high left ventricular ejection fraction if the systolic function is not disturbed. The 
fact that in most people the left ventricular dimensions were within the normal 
range adds weight to our interpretation that systolic function is relatively intact, 
and left ventricular ejection fraction among very old participants may not provide 
a valid estimation of cardiac function. Although the E/A ratio is frequently used 
as an indicator of diastolic function, it is a limitation of our study that we have not 
assessed other measures of diastolic dysfunction. 
One of the strengths of our study is the population-based character. However, 
the present analysis is limited due to the inclusion of relatively vital participants. 
The differences in general performance, cognitive performance (MMSE) and 
activities of daily living between the participants with versus those without an 
echocardiography underlined this bias towards health. Although the findings can 
thus not be applied to old people with ill health, one may argue that the adaptive 
responses as shown for those in good health, are exaggerated in those 90-year-
old subjects who are less vital. The relatively small sample size prohibits us from 




The clinical consequences of these new unexpected echocardiographic findings 
have clinical significance. Physicians must be aware that a ‘normal’ blood pressures 
in the very old, for example non-hypertensive blood pressure values, does not 
guarantee a healthy cardiovascular state but may reflect cardiac dysfunction. 
Furthermore, the assessment of left ventricular ejection fraction only, to mark 
cardiac failure is insufficient as systolic function in old age is relatively conserved. 
Stroke volume index and cardiac output, together with heart rate, better identify 
older people at risk. Proper cardiac evaluation in those patients might open 
treatment modalities and hence improve prognosis.
Source of funding
This study was partly supported by an unrestricted grant from the Dutch Ministry 
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Background: The present study evaluated the prevalence of significant valvular 
heart disease in community dwelling nonagenarians. In addition, we evaluated 
the impact of valvular heart disease on the ability to perform activities of daily 
living.  
Methods: Nested within the Leiden 85-plus study, a population based follow-
up study of the oldest old, a sample of 81 nonagenarians was recruited. The left 
ventricular (LV) dimensions, function and the presence and severity of heart 
valvular disease were evaluated by echocardiography. Significant valvular heart 
disease included any mitral or aortic stenosis severity, moderate or severe mitral 
regurgitation, moderate or severe aortic regurgitation and moderate or severe 
tricuspid regurgitation. Daily life activities were assessed using the Groningen 
Activity Restriction Scale (GARS).
Results: LV cavity diameters (end-diastolic diameter 47 ± 8 mm, end-systolic 
diameter 30 ± 8 mm) and systolic LV function (LV ejection fraction 66 ± 13%) were 
within normal for the majority of the participants. Significant valvular disease was 
present in 57 (70%) individuals, with mitral regurgitation and aortic regurgitation 
as the most frequent valve diseases (49% and 28% respectively). The GARS score 
between individuals with and without significant valvular heart disease was 
similar (36.2 ± 9.2 vs. 34.4± 13.2, p=0.5). 
Conclusions: Nonagenarian, outpatient individuals have a high prevalence of 
significant valvular heart disease. However, no relation was observed between the 
presence of significant valvular heart disease and the ability to perform activities 
of daily living.




The increasing life expectancy of the population in the Western countries has 
determined an increase of chronic diseases, with cardiovascular disease being one 
of the most prevalent pathologies.1 The elderly individuals comprise a growing 
demographic subgroup characterized by a high frequency of cardiovascular risk 
factors and co-morbidities.2 Furthermore, this subgroup of individuals is often 
excluded from randomized trials, resulting in important implications for clinical 
management.3, 4 Particularly, data on the prevalence of valvular heart disease in 
very old individuals are scarce and based mostly on in-hospital series, introducing 
an important selection bias.4-7 In addition, the potential detrimental effect of 
valvular heart disease on the daily living activity is unknown. 
Accordingly, the aim of the present study was twofold. First, the prevalence 
of significant valvular heart disease was evaluated in a group of outpatient 
individuals aged 90 years. Furthermore, the impact of significant valvular heart 
disease on the competence in different activities of daily living was studied. 
Significant valvular heart disease was defined according to the Euro Heart Survey 
on Valvular Heart Disease.4
Methods
Study protocol
The Leiden 85-plus Study is a prospective population-based study of all 85-year 
old inhabitants of Leiden, The Netherlands. The study design and characteristics 
of the cohort were described in detail previously.8, 9 In short, between September 
1997 and September 1999 all 705 members of the 1912 to 1914-birth cohort in the 
city of Leiden were asked to participate in the month after their 85th birthday. 
There were no selection criteria related to health or demographic characteristics. 
Participants were followed until death or the age of 90 years. At baseline and 
yearly thereafter, 85-year old participants were visited at their place of residence. 
During these visits blood pressure was measured, a venous blood sample drawn, 
an electrocardiogram recorded and face-to-face interviews and performance tests 
conducted. At 90 years of age, the participants were invited for an echocardiographic 
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examination. Participants gave informed consent and for individuals who were 
severely cognitively impaired, a guardian gave informed consent. The Medical 
Ethics Commission of Leiden University approved the study.
Clinical evaluation
Clinical status was evaluated in all individuals using the Groningen Activity 
Restriction Scale (GARS), 1-dimensional questionnaire that assess the performance 
in basic and instrumental activities of daily living (ADL and IADL).10 The score 
ranges from 18 to 90, higher scores indicating increasing disability. Cognitive 
function was assessed by the Mini-Mental State Examination (MMSE), with scores 
ranging from 0 to 30 points (optimal).10 Depressive symptoms were measured 
in those with MMSE > 18 points, using the 15-item Geriatric Depression Scale 
(GDS-15), with scores ranging from 0 (optimal to 15 points).10 A GDS-15 score 
above 4 was considered to be poor. Furthermore, the cardiovascular history was 
recorded, including history of coronary artery disease (medical history of angina 
or myocardial infarction), bypass surgery, stroke, and peripheral vascular disease.9 
Heart failure was defined as a positive response of the general practitioner to a 
specific question. 
Blood pressure was measured twice with an interval of two weeks, using a 
mercury sphygmomanometer, in seating position after at least five minutes rest 
without having performed vigorous exercise during the preceding 30 minutes. We 
used the mean of the assessed systolic values and diastolic values.
Echocardiography
Transthoracic 2-dimensional echocardiography was performed in all individuals 
in the left lateral decubitus position. Images were obtained using a commercially 
available system equipped with a 3.5-MHz transducer (Vingmed system Vivid-5; 
General Electric-Vingmed, Milwaukee, WI, USA). Standard gray-scale and color 
Doppler images were acquired at a depth of 16 cm at the parasternal (standard 
long- and short-axis images) and apical views (2-, 4-chamber and apical long-axis 
images). Data were stored for further off-line analysis. 
Left ventricular (LV) diameters, interventricular septal (end-diastolic) thickness 
and posterior wall (end-diastolic) thickness were measured from M-mode images 
obtained from the parasternal long-axis view, and LV ejection fraction was 
Valvular heart disease in nonagenarians.
95
6
derived using the Teichholz formula.11 Left ventricular mass was calculated by 
the cube formula, using the correction formula proposed by Devereux et al.12 Left 
ventricular mass was indexed by the body surface area. According to previous 
criteria, LV hypertrophy was defined by a LV mass index > 110 g/m2 in women 
and >134 g/m2 in men.12 Finally, left atrial dimension was calculated by measuring 
the anteroposterior diameter from M-mode recordings of the parasternal long-
axis view.
Left ventricular diastolic function was evaluated by measuring the transmitral 
peak velocities (E-wave and A-wave) obtained from pulsed-wave Doppler 
recordings of the transmitral inflow velocity; from these velocities the E/A ratio 
derived as another marker of LV diastolic function.13
The valvular assessment included the evaluation of the function of the mitral, 
aortic and tricuspid valves. Color-Doppler echocardiography was performed 
after optimizing gain and Nyquist limit, and standard continuous and pulsed-
wave Doppler recordings were acquired. Stenotic and regurgitant valve diseases 
were evaluated according to semiquantitative and quantitative methods 
recommended by the American Society of Echocardiography.13, 14 The severity of 
valvular stenosis was based on the valve area and the mean pressure gradient 
across the restrictive orifice.15 The mitral valve area was calculated by the pressure 
half-time and the aortic valve area was calculated by the continuity equation.13, 
16 The mean pressure gradient across the restrictive orifice was estimated by 
averaging the instantaneous gradients obtained from continuous wave Doppler 
recordings.13 In addition, the severity of valvular regurgitation was determined 
on a qualitative scale and classified as mild (grade 1), moderate (grade 2) and 
severe (grades 3-4), according to the current ACC/AHA guidelines for the 
management of individuals with valvular heart disease.15 According to the Euro 
Heart Survey on Valvular Heart Disease, significant valvular disease was defined 
as any mitral or aortic stenosis severity, moderate or severe mitral regurgitation, 
moderate or severe aortic regurgitation.4 In addition, moderate or severe tricuspid 
regurgitation was considered as significant valvular heart disease. Finally, when 
tricuspid regurgitation was present, the pulmonary artery pressure was estimated 




Continuous variables are presented as mean ± SD and categorical variables are 
presented as number and percentages. Differences between individuals with 
significant valvular disease and individuals without valvular disease were 
compared by the 2-tailed Student t-test, ANOVA, Mann-Whitney test and c2-test 
for unpaired data, when appropriate. All statistical analyses were performed with 
software SPSS for Windows version 12.0 (SPSS, Inc., Chicago, IL). A p value <0.05 
was considered statistically significant.
Results
Of the initial 705 eligible participants at the Leiden 85–plus study, 14 died before 
they could be enrolled and 92 refused to participate, resulting in a cohort of 599 
participants who could be enrolled at age 85 (87% response). Some 277 participants 
survived up to age 90 years and were in principle eligible for the study. Among 
them, 81 outpatient individuals underwent echocardiography. The remaining 
196 individuals were not able to visit the study center. Clinical and demographic 
characteristics are presented in Table 1. All individuals with echocardiographic 
examination were 90 years old (33% men). The majority of the individuals were in 
sinus rhythm (93%). The mean body surface area was 1,7 m2 [SD ± 0.7]. 
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Table 1. Clinical and demographic characteristics 
Echocardiograpic examination
Yes [n=81] No [n=196] p value
Females [%] 67 75 0.20*
Living independently [%] 78 55 <0.001*
ADL (IQR) [points] 10 (9-14) 16 (10-25) <0.001‡
IADL (IQR) [points] 23 (17-29) 33 (25-36) <0.001‡
GARS (IQR) [points] 33 (26-42) 49 (35-61) <0.001‡
MMSE (IQR) [points] 28 (26-29) 22 (15-27) <0.001‡
GDS-15 (>4) [%] 14.8 32 <0.001‡
History of cardiovascular disease [%]† 35 43 0.15*
History of heart failure [%] 19 17 0.82*
Diastolic blood pressure (SD) [mmHg] 73 (9) 71 (10) 0.17*
Systolic blood pressure (SD) [mmHg] 155 (16) 150 (19) 0.03*
SD, Standard Deviation. IQR, Inter Quartile Range. ADL, Activities in Daily Living. IADL, 
Instrumental Activities in Daily Living. GARS, Groningen Activity Restriction Scale. 
MMSE, Mini Mental State Examination. GDS-15, Geriatric Depression Scale. †, Including 
cerebrovascular accident, angina pectoris, myocardial infarction, peripheral vascular 
disease or an electrocardiogram revealing myocardial ischemia or infarction. *, Independent 
T-test. ‡, Mann Whitney test. N, number of participants. 
Echocardiography
The echocardiographic characteristics of the study population are summarized 
in Table 2. The majority of the individuals showed normal LV dimensions and 
preserved systolic LV function. Seven (9%) individuals had LV systolic dysfunction 
(LV ejection fraction <50%). According to the previous definition, LV hypertrophy 
was present in 40 (51%) individuals, without differences between men and women 
(12 (44%) vs. 28 (55%), respectively; p=0.5). Mean anteroposterior diameter of the 
left atrium was 42 ± 9 mm. An enlarged left atrium (anteroposterior diameter > 
40 mm) was present in 43 (53%) individuals. Evaluation of LV diastolic function 
demonstrated impaired LV relaxation in the majority of the individuals, reflected 
by an E/A ratio <1.
Data on heart valve study are presented in Table 3. Significant valvular disease 
was observed in 57 (70%) individuals. Significant left-sided valvular disease 
involving only one valve (mitral or aortic) was noted in 38 (47%) individuals, 
whereas 23 (28%) individuals had both the mitral and the aortic valves involved. 




Mitral and aortic regurgitation were the most common valvular diseases 
diagnosed and no patient had mitral stenosis. Significant mitral regurgitation 
was observed in 39 (49%) individuals: 24 (30%) individuals had moderate 
mitral regurgitation and 15 (19%) individuals had severe mitral regurgitation. 
Significant aortic regurgitation was observed in 23 (28%) individuals: 17 (21%) 
individuals had moderate aortic regurgitation and 6 (7%) individuals had severe 
aortic regurgitation. Aortic stenosis was present in 14 (17%) individuals: 9 (11%) 
individuals had mild aortic stenosis, 4 (5%) individuals had moderate aortic 
stenosis and only 1 (1%) patient had severe aortic stenosis. Finally, moderate to 
severe tricuspid regurgitation was observed in 17 (21%) individuals, together 
with significant left-sided valvular heart disease. The mean (SD) pulmonary 
artery pressure in these individuals was 35 (± 7) mmHg.
Table 2. Left ventricular dimensions and function
Mean [SD]
LV end-diastolic diameter (mm) 47 ± 8
LV end-systolic diameter (mm) 30 ± 8
Interventricular septum thickness (mm) 13 ± 3
Posterior wall thickness (mm) 11 ± 2
LV ejection fraction (%) 66 ± 13
LV mass index (g/m2) 126 ± 37
Left atrium diameter (mm) 42 ± 9
E/A ratio 0.7 ± 0.2
81 participants included. LV = left ventricular. SD=Standard Deviation.
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Table 3. Valvular heart disease in the study population
Mitral Valve
- Mitral stenosis (%)










- Aortic stenosis (%)
- Mild (mean ΔP < 25 mmHg)
- Moderate (mean ΔP 25 – 40 mmHg)
- Severe (mean ΔP > 40 mmHg)













- Tricuspid stenosis (%)









81 participants included. ΔP = pressure gradient.







Ability to perform activities of daily living and heart valvular disease
Differences in functional status as assessed by the GARS score were evaluated 
between individuals with and without significant valve disease. Patients with 
and without moderate or severe valvular heart disease showed comparable GARS 
score: 34.8 ± 13.4 vs. 34.8 ± 9.4, p = 0.97. Furthermore, there were no differences in 
the GARS score between individuals without, one or two valves being significantly 
diseased (p=0.6) (Table 4).














Mean (SD) 36.2 ± 9.2 34.4 ± 13.2 * 35.4 ± 14.4 32.7 ± 11.1 †‡
N=number of participants. * p = 0.5 vs. No valvular heart disease. † p = 0.4 one valve 
diseased vs. two valves diseased. ‡ ANOVA p-value = 0.6 No valvular disease vs. one and 
two valves diseased. SD=Standard Deviation.
Discussion
The findings in the current study illustrate that the majority of the nonagenarian 
outpatient individuals have normal LV cavity dimensions and normal systolic LV 
function on echocardiography. However, the prevalence of significant valvular 
disease is high, with mitral and aortic valve regurgitation being the most frequent 
valvular diseases. Nonetheless, the presence of significant valvular disease does 
not impact negatively on the functional status assessed with the GARS score. 
Echocardiographic characteristics of the nonagenarian population
The nonagenarian outpatient population evaluated in the present study showed 
normal LV cavity dimensions and preserved systolic LV function. In contrast, 
diastolic LV function was characterized mostly by impaired LV relaxation. 
Several previous studies have reported similar findings in elderly individuals, 
with normal values of LV diameters and preserved systolic LV function, but with 
different grades of diastolic dysfunction.6, 17 As previously described, the aged-
related changes in cardiac structure comprise a progressive increase in LV wall 
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thickness whereas LV diameters and systolic LV function remain unchanged.18 In 
addition, the increasing LV stiffness and collagen deposition that accompany the 
patient’s aging, result in delayed LV relaxation and impairment of the early LV 
diastolic filling.18 All these changes were observed in the present study, with an 
increased LV mass index (126 ± 37 g/m2) together with normal LV cavity diameters. 
Furthermore, various indices of diastolic dysfunction were abnormal (e.g. an E/A 
ratio <1 or an enlarged left atrium) indicating impaired LV compliance. 
However, all these structural and functional changes are strongly influenced by 
the presence of cardiovascular disease (i.e. coronary artery disease, valvulopathies 
or hypertension), the most common co-morbidity among the elderly individuals. 
Importantly, a high prevalence of valvular heart disease was observed in the 
present study population, with mitral and aortic valve regurgitation as the most 
frequent valvulopathies. Several contemporary series from Europe and the 
United States have demonstrated the relation between aging and the prevalence 
of degenerative valvular heart disease.4, 6, 7, 19 However, the true burden of valve 
disease remains still unclear since the majority of those series included in-hospital 
individuals or individuals referred for valvular surgery, introducing an important 
selection bias.4, 6, 7 Recently, Nkomo et al. demonstrated, in a community study 
including 3851 individuals older than 75 years, high absolute rates of significant 
valvular heart disease (11.7%), with mitral regurgitation and aortic stenosis being 
the most frequent valve diseases (7.1% and 4.6%, respectively).7 Furthermore, 
Sadiq et al. evaluated the distribution pattern of moderate to severe valve disease 
among 63 hospitalised centenarian individuals, a significant minority of them 
admitted because cardiovascular events (35%).6 In that study, aortic stenosis was 
the most prevalent valve disease (27%) followed by mitral regurgitation (22%) and 
aortic regurgitation (17%).6 Whereas in the aforementioned series the population 
comprised individuals with known valve disease or in-hospital individuals,6, 7 the 
present population consisted of clinically stable and mostly independently living 
nonagenarians from the general population. The high prevalence of valvular 
heart disease as observed in the present study when compared to previous studies 
is difficult to explain because of the different clinical characteristics. As previously 
described, aortic stenosis is characterized by poor clinical tolerance and, therefore, 
may determine higher hospital admission rates and higher prevalence of this 
particular valve disease in the inpatient-based series. 
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Impact of valvular disease on the ability in daily-life activities 
In the current study, the competence in basic and instrumental activities of daily 
living was evaluated using the GARS score and related to the presence of valvular 
heart disease. Importantly, no differences in GARS score were observed between 
individuals with and without significant valve disease.
The relation between the impairments of basic activities of daily living and 
instrumental activities of daily living and cardiovascular co-morbidities has 
not been extensively studied.20, 21 Maugeri et al. related several parameters (e.g. 
walking speed, cognitive function, personal care) to systolic LV function in 170 
individuals older than 70 years.21 The authors demonstrated significant functional 
disability in those individuals with heart failure, whereas individuals with 
preserved systolic LV function obtained better scores in the tests.21 In contrast, 
Formiga et al. evaluated the predictors of functional decline in 97 nonagenarians 
at 1 year follow-up and identified a history of stroke as an independent risk factor 
whereas the history of ischemic cardiomyopathy or heart failure were not related 
to functional decline.20
The current study demonstrated that no relation existed between the ability in 
daily life activities and the presence of significant valvular heart disease. Of note, 
the preserved systolic LV function observed in the majority of the population 
could preclude us to find differences in functional status between individuals 
with and without significant valve disease. Additional large studies, including 
individuals with a broad range of systolic LV function, may provide more insight 
into the relation between the competence in daily life activities and the presence 
of valvular heart disease.
Study Limitations
The present study population represents a selected group of outpatient 
nonagenarians and therefore, the results may not apply to the general population 
of nonagenarians.
Although, the GARS score is a validated score reflecting the limitations in daily 
life other more physical tests might have been more appropriate to use. However, 
the GARS score gives a valuable insight in the limitations of daily life that was 
related to valve dysfunction. That there is no apparent difference in those with 
versus those without significant valve dysfunction is therefore remarkable.




The nonagenarian population has high prevalence of significant valvular heart 
disease, in the presence of preserved systolic LV function, without LV dilatation. 
The presence of significant valve disease did not impact negatively on the ability 
to perform activities of daily living. Therefore, in this age group one should be 
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To investigate markers of autonomic tone on a standard electrocardiogram in 
relation to mortality in old age.
Methods 
A total of 599 inhabitants of Leiden, the Netherlands, were enrolled in a 
population-based follow up study at their 85th birthday. Electrocardiograms 
were taken on entry and annually thereafter. ECGs were analysed automatically 
to determine four markers of autonomic tone, i.e. heart rate, the occurrence of 
ventricular extrasystoles and two time domain measures of heart rate variability. 
All participants were followed up for mortality. 
Results
Participants with a heart rate in the highest quartile had a 1.8-fold increased total 
mortality risk (95% CI 1.0-3.4), but not an increased cardiovascular mortality 
risk. The occurrence of at least one ventricular extrasystole was related with a 
2.3-fold increased total mortality risk (95% CI 1.3-3.9) and a 3.6-fold increased 
cardiovascular mortality risk ( 95% CI 1.6-8.2). In stratified analyses, the prognostic 
effect was confined to males. Both measures of heart rate variability were not 
related to mortality.
Conclusions
High heart rate and the occurrence of a ventricular extrasystole, both markers 
of sympathetic dominance, were predictive for mortality in old age. Two 
short-term measures of heart rate variability as measured on a standard 10 
sec. electrocardiogram were not related to mortality, and hence may not reflect 
autonomic tone in old age.




Altered autonomic activity resulting in sympathetic dominance leads to an excess 
of cardiovascular and non-cardiovascular mortality (1,2). The exact mechanism is 
not clear but among others, cardiac arrhythmias and accelerated atherosclerosis 
have been mentioned (3,4). Markers of autonomic activity are therefore of 
important prognostic value. 
Heart rate and heart rate variability are the most common reflections of the 
balance of the parasympathetic/sympathetic nervous system (5). High heart rate 
(e.g. reflecting more sympathetic dominance) has repeatedly been associated 
with all cause, non-cardiovascular and cardiovascular mortality (6-12). Low heart 
rate variability (e.g. reflecting more sympathetic dominance), as measured on a 
24-hour recording, has also been associated with all cause and cardiovascular 
mortality (13-15). For prognostic values the 5-min recording and the 24-hour 
recording have been recommended (15). However, a 10-second estimate of heart 
rate variability correlates highly with a similar estimate from a 5-min recording 
and the repeatability of the 5-min recording was found to be reasonable (16,17). 
Nevertheless, heart rate variability measured on a standard electrocardiogram 
has not been widely assessed and three population-based studies that have used 
such an approach showed conflicting results (18-20). In addition, these discordant 
findings are reinforced in a recent study in which the prognostic value of heart 
rate variability as measured on a standard electrocardiogram and on a 24-hour 
recording are compared; only the 24-hour recording had prognostic value (21).
A spontaneous increased sympathetic tone is involved in the genesis of ventricular 
extrasystoles (22). In addition a single ventricular extrasystole provokes a burst of 
sympathetic activity (23). Thus, ventricular extrasystoles are associated with an 
increased activity of sympathetic activity and, therefore, they can be used as a 
marker of sympathetic activity. The average of the absolute values of the beat-to-
beat differences between normal consecutive RR intervals (AAD) has been shown 
to be a sensitive marker for parasympathetic activity (24). AAD is longer when 
parasympathetic influence is more prominent but its predictive value in clinical 
outcome studies has not been assessed as yet. 
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The aim of this study was to determine the association between mortality and 
markers of parasympathetic/sympathetic balance, i.e. heart rate, ventricular 
extrasystoles and two measures of heart rate variability as measured on the 
standard 10 seconds electrocardiogram. 
Methods
Study population
The Leiden 85-plus Study is a prospective population-based study of all 85-year 
old inhabitants of Leiden, The Netherlands. The study design and characteristics 
of the cohort were described in detail previously (25, 26). In short, between 
September 1997 and September 1999 all 705 members of the 1912 to 1914-birth 
cohort were asked to participate in the month after their 85th birthday. There were 
no selection criteria related to health or demographic characteristics. At baseline, 
participants were visited three times at their place of residence. During these visits, 
face-to-face interviews were conducted and an electrocardiogram was recorded. 
During follow-up, an electrocardiogram was recorded yearly. Participants gave 
informed consent and for people who were severely cognitively impaired, their 
guardians gave informed consent. The Medical Ethics Commission of Leiden 
University approved the study. 
Electrocardiogram
Standard 10 seconds electrocardiograms were recorded annually on a Siemens 
Sicard 440 and transmitted by telephone to the ECG Core Lab in Glasgow and 
analysed automatically (27). Only electrocardiograms with sinus rhythm were 
included in our analysis. In addition, all electrocardiograms with ectopic atrial 
rhythm, second- or third-degree AV-block, supraventricular or ventricular 
extrasystoles were excluded for assessment of heart rate and heart rate variability. 
Two measures of heart rate variability were studied, namely the standard deviation 
of the normal-to-normal RR-interval (SDNN), and the average of the absolute 
values of the beat-to-beat differences between normal consecutive RR intervals 
(AAD). Essentially, the onset of every QRS complex in the 10-second recording is 
determined and RR intervals are therefore calculated thereafter. For the analysis 
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of ventricular extrasystoles, only electrocardiograms with sinus rhythm and at 
least one ventricular extrasystole were analysed. 
Mortality
All subjects were followed up for mortality till age 89 years. Shortly after the civil 
registry reported the death of a subject, the general practitioner or nursing home 
physician was interviewed to obtain the cause of death using a standardized 
questionnaire. Two senior specialists of internal medicine determined the primary 
causes of death by consensus according to the tenth version of the International 
Classification of Diseases (ICD-10) independent of ECG results (28). Primary 
causes of death were divided into two groups: cardiovascular mortality (ICD-
codes I00-I99, I20-I25 and I60-I69) and non-cardiovascular mortality (all other 
ICD-codes).
Morbidity and demographic characteristics
At baseline, a research nurse collected information concerning the housing 
situation of each participant. The Mini-Mental State Examination (MMSE) 
was administered to screen for cognitive impairment (29). The presence of 
cardiovascular disease was defined as a positive medical history of cerebrovascular 
accidents, angina pectoris, myocardial infarction, peripheral vascular disease or 
an electrocardiogram revealing myocardial ischaemia or infarction (Minnesota 
codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-2 and 5-3) (27).
Statistical analysis
Data are presented as percentages for clinical characteristics. Heart rate and heart 
rate variability were divided into quartiles, based on the distribution of all ECGs. 
Several ECGs per participant are included in this analysis. Mortality risks and 95% 
confidence intervals for both cardiovascular and non-cardiovascular mortality 
were estimated in a Cox proportional-hazards model including the data from the 
annual repeated electrocardiograms as time dependent covariates (30). For the 
analyses of the two heart rate variability measures, we have used heart rate as an 
additional time dependent covariate. The observed survival time was restricted to 
a period of a maximum of one year after the assessment of an electrocardiogram, 





Of the 705 eligible participants, 14 died before they could be enrolled and 92 
refused to participate, resulting in a cohort of 599 participants (87 % response). 
204 (34%) participants were males and 395 participants (66%) were females. Signs 
or symptoms of cardiovascular disease were present in 62% of participants at 
baseline (23). The demographic characteristics of the 449 participants with an ECG 
showing sinus rhythm at baseline are given in table 1. During the 4-year follow 
up period subjects were observed for a total of 1906 person years. A total of 1822 
ECGs were available for evaluation. 84 ECGs were missing because of technical 
problems. 
Table 1: Clinical characteristics of participants at baseline.
n= 449 (100%) 
Male 31,6% 
Living independently 84,6%
Good cognitive function* 64,1%
History of cardiovascular disease† 60,1%
* Mini Mental State Examination >24.
†Based on medical history and ECG findings.
During the follow-up, we observed 70 deaths of which 18 were caused by 
cardiovascular disease. When mortality risk was analysed dependent on heart 
rate for all participants, the participants in the highest quartile (heart rate of more 
than 74 per minute) had a 1.8-fold mortality risk from all causes (95% CI 1.0-3.4, 
p=0.038) and a 2.2 fold non-cardiovascular mortality risk (95% CI 1.0-4.9, p=0.019) 
when compared to the participants in the lowest quartile (heart rate less than 60 
per minute). There was no increase in cardiovascular mortality dependent on 
heart rate (data not shown). When we stratified for gender, there seemed to be 
a trend towards a higher risk for all cause and non-cardiovascular mortality in 
males (table 2), whereas there was no association with heart rate and mortality 
in females (table 2). The estimates for heart rate and mortality risks were not 
different in participants with or without cardiovascular disease at baseline (data 
not shown). In addition, the estimates for heart rate and mortality risks were not 
different in participants with or without cognitive impairment (dichotomised on 
a MMSE value of 24 points, data not shown).
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Table 2: Mortality risk dependent on quartiles of heart rate, stratified for gender.
Quartiles of heart rate (beats per minute)
< 60 60 – 67 68 – 74 > 74
Males n=330
   All cause 1* 1.2 (0.3-4.4) 2.2 (0.7-7.2) 3.0 (1.0-9.1)†
   Cardiovascular 1* 0.7 (0.07-8.0) 0.9 (0.08-10) 1.8 (0.3-13)
   Non-cardiovascular 1* 1.5 (0.3-7.5) 3.1 (0.7-13) 3.8 (0.9-15)‡
Females n=812
   All cause 1* 0.8 (0.3-1.8) 0.8 (0.4-1.9) 1.3 (0.6-2.9)
   Cardiovascular 1* 0.7 (0.2-2.9) 0.2 (0.02-1.8) 0.9 (0.2-3.5)
   Non-cardiovascular 1* 0.8 (0.3-2.3) 1.2 (0.4-3.0) 1.6 (0.6-4.0)
Data presented as mortality risks (95% confidence intervals) from Cox proportional-
hazards model with the quartiles of heart rate as time dependent covariate. Based on 
1457 automatically included electrocardiograms with sinus rhythm, minus 315 manually 
excluded electrocardiograms with ventricular or supraventricular extrasystoles, ectopic 
atrial rhythm, second or third degree AV-block.
* Reference category; † p=0.058; ‡ p=0.062
In a similar analysis, as described above, all participants who had sinus rhythm 
and ventricular extrasystoles suffered a significant increased mortality risk from 
all causes (RR 2.3, CI 1.3-3.9) and from cardiovascular causes (RR 3.6, CI 1.6-
8.2) as compared to the participants without a ventricular extrasystole. After we 
stratified for gender, the presence of ventricular extrasystoles was still predictive 
for all cause, cardiovascular and non-cardiovascular mortality in males (table 3). 
In females there was no association between mortality risk and the occurrence of 
ventricular extrasystole (table 3). The estimates for ventricular extrasystole and 
mortality risks were not different in participants with or without cardiovascular 
disease at baseline (data not shown). In addition, the estimates for ventricular 
extrasystole and mortality risks were not different in participants with or without 
cognitive impairment (dichotomised on a MMSE value of 24 points, data not 
shown).
In contrast to the analyses mentioned above, heart rate variability was not 
associated with all cause mortality or cardiovascular mortality (table 4). 
Stratification for gender did not change this lack of association (data not shown). 
As heart rate variability is dependent on heart rate, we adjusted for heart rate. 
However, after this adjustment heart rate variability still had no predictive value 
in relation to mortality (table 4).  
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Table 3: Mortality risk dependent on the presence of ventricular extrasystole, stratified 
for gender.
No ventricular extrasystole Ventricular extrasystoles
Males n=35
   All cause 1* 4.5 (2.3-9.0)
   Cardiovascular 1* 6.4 (2.2-19)
   Non-cardiovascular 1* 3.7 (1.5-9.2)
Females n=64
   All cause 1* 1.0 (0.4-2.7)
   Cardiovascular 1* 1.8 (0.4-7.9)
   Non-cardiovascular 1* 0.7 (0.2-2.7)
Data presented as mortality risks (95% confidence intervals) obtained from Cox 
proportional-hazards model with the presence of ventricular extrasystoles as time 
dependent covariate. Based on 1457 automatically analysed electrocardiograms with sinus 
rhythm, of which 99 had one or more ventricular extrasystoles. During follow-up 16 deaths 
(8 of cardiovascular disease) occurred among the participants who had sinus rhythm and 
ventricular extrasystoles.
* Reference category
Table 4: Mortality risk dependent on heart rate variability.
Quartiles of heart rate variability
< 9.1 ms 9.1 – 14.9 ms >14.9 – 26.4 ms >26.4 ms
Crude
   All cause 1* 0.77 (0.42 – 1.4) 0.58 (0.30 – 1.1) 0.72 (0.39 – 1.4)
   Cardiovascular 1* 0.60 (0.14 – 2.5) 0.96 (0.28 – 3.3) 0.99 (0.29 – 3.4)
   Non-cardiovascular 1* 0.82  (0.47 – 1.6) 0.47 (0.21 – 1.1) 0.65 (0.31 – 1.3)
Adjusted for heart rate 
   All cause 1* 0.85 (0.45 – 1.6) 0.66 (0.34 – 1.3) 0.87 (0.45 – 1.7)
   Cardiovascular 1* 0.60 (0.14 – 2.6) 0.97 (0.27 – 3.5) 0.98 (0.32 – 4.2)
   Non-cardiovascular 1* 0.92 (0.46 – 1.8) 0.56 (0.25 – 1.3) 0.83 (0.39 – 1.8)
Data presented as mortality risks (95% confidence intervals) obtained from Cox 
proportional-hazards model with the quartiles of heart rate variability as a time dependent 
covariate, adjusted for gender. Based on 1457 automatically included electrocardiograms 
with sinus rhythm, minus 315 manually excluded electrocardiograms with ventricular or 
supraventricular extrasystoles, ectopic atrial rhythm or second or third degree AV-block.
* Reference category
No association was found between AAD and all cause mortality or cardiovascular 
mortality (table 5). Stratification for gender did not change the lack of association 
(data not shown). As AAD is dependent on heart rate also, we adjusted for heart 
rate. However, after adjustment, AAD still had no predictive value (table 5).
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Table 5: Mortality risk dependent on quartiles of the average of the absolute values of 
the beat-to-beat differences (AAD) between normal consecutive RR intervals.
Quartiles of the absolute difference of the beat-to-beat variations
                                        < 8,0 ms 8,0 – 13,6 ms 13.7 – 24.0 ms > 24.0 ms
Crude
   All cause 1* 0.74 (0.37 – 1.5) 1.1 (0.58 – 2.0) 0.88 (0.46 – 1.7)
   Cardiovascular 1* 1.1 (0.27 – 4.2) 1.0 (0.25 – 4.1) 1.6 (0.44 – 5.6)
   Non-cardiovascular 1* 0.65 (0.30 – 1.4) 1.1 (0.54 – 2.1) 0.70 (0.32 – 1.5)
Adjusted for heart rate
   All cause 1* 0.86 (0.43 – 1.7) 1.4 (0.71 – 2.6) 1.2 (0.58 – 2.3)
   Cardiovascular 1* 1.2 (0.28 – 4.7) 1.1 (0.27 – 4.9) 1.7 (0.43 – 6.8)
   Non-cardiovascular 1* 0.77 (0.35 – 1.7) 1.4 (0.69 – 2.9) 1.0 (0.44– 2.3)
Data presented as mortality risks (95% confidence intervals) obtained from Cox proportional-
hazards model with the quartiles of the absolute difference of the beat-to-beat variations 
as a time dependent covariate, adjusted for gender. Based on 1457 automatically included 
electrocardiograms with sinus rhythm, minus 315 manually excluded electrocardiograms 




This study has shown that ventricular extrasystoles as measured on a standard 
electrocardiogram, are predictive of cardiovascular and non-cardiovascular 
mortality in older men from the general population. Higher heart rate as measured 
on a standard 10 seconds electrocardiogram, seems to be predictive for all cause 
and non-cardiovascular mortality in older men from the general population also. 
However, neither heart rate variability nor AAD was predictive of cardiovascular 
or non-cardiovascular mortality in males or females. 
The predictive value of heart rate variability, as measured on long-term 
electrocardiogram recording, for mortality is well established (13-15, 31). In contrast, 
the predictive value of heart rate variability on a standard electrocardiogram is 
not clear. Three population-based studies have used a standard electrocardiogram 
for determining heart rate variability. The Rotterdam Study found an increased 
all cause mortality risk for all participants (mean age 69 years) in both the lowest 
and the highest quartile of heart rate variability compared with the third quartile 
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(18). Furthermore, mortality from cardiovascular causes was 2-fold increased 
among participants in the lowest and highest quartile. The Zutphen Study, which 
included only middle-aged men, found a 2-fold increased all cause mortality risk 
when the lowest and highest quartile of heart rate variability were compared (19). 
The two studies mentioned above did not correct for heart rate. It remains to be 
established whether the above found correlations remain after correction for heart 
rate. This reasoning is reinforced by the Bronx Aging Study (mean age 79 years) 
that did not find any difference in mortality between participants with high versus 
low heart rate variability (20). Heart rate variability as measured on a standard 
electrocardiogram at discharge of patients with an acute myocardial infarction 
had no predictive value for mortality, whereas heart rate variability measured on 
a 24-hour recording was highly predictive of cardiovascular mortality (21).
The prognostic value of AAD has not yet been established. As a sensitive 
marker of parasympathetic activity (16,24), we speculated that a more dominant 
parasympathetic activity is related with les cardiovascular mortality. However, 
we did not find a correlation between mortality and a longer AAD, i.e. more 
parasympathetic influence on a standard ECG recording.
The lack of prognostic information of the heart rate variability and AAD could mean 
that the parasympathetic / sympathetic balance in the general population of old 
people is not predictive of mortality. However, the association between heart rate 
and ventricular extrasystoles with overall mortality and cardiovascular mortality 
are at odds with this view. Heart rate is a reflection of the parasympathetic / 
sympathetic balance, a higher heart rate reflecting a dominance of the sympathetic 
nervous system. In line with this, various studies reported a high heart rate 
to be predictive of overall mortality, non-cardiovascular and cardiovascular 
mortality (6-12). Ventricular extrasystoles are another reflection of the activity 
of the sympathetic nervous system (22,23). The occurrence of three or more 
ventricular extrasystoles per hour on 24-hour ECG recordings in patients with 
a myocardial infarction predicted higher rates of mortality (32). Taken together, 
the data show that markers of parasympathetic/sympathetic balance –e.g. heart 
rate and the occurrence of a ventricular extrasystole- are predictive of mortality. 
The lack of prognostic value of heart rate variability and AAD as measured on a 
standard electrocardiogram could mean that they are not a reliable reflection of 
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the parasympathetic / sympathetic balance. The reason for this lack of association 
is not clear. It could well be, that in this age group, there is an increased heart rate 
variability due to different foci being involved in stimulating the atria, although 
in the main, we have been reported this as sinus rhythm. In other words, in this 
very elderly age group, there is an intrinsic increase in heart rate variability, which 
will mask any “impaired” heart rate variability. A concern might be that heart rate 
variability is more sensitive to the somewhat uncontrolled conditions in obtaining 
ECGs compared to ventricular extrasystoles. However, we found a prognostic 
effect of heart rate on mortality also, even though heart rate is known to be very 
sensitive to short term influences. Therefore, we think that the lack of association 
between heart rate variability and mortality is not due to conditions in where the 
ECGs were obtained.
Other studies did not correct for heart rate, but because we used only a short-
term recording, the heart rate could potentially influence heart rate variability, 
i.e. with a lower heart rate, heart rate variability tends to be larger and vice 
versa. However, after adjustment for heart rate there was no material change in 
outcome. The short-term recording could also influence the results of AAD in the 
same manner, i.e. with a lower heart rate; there is a longer absolute difference of 
the beat-to-beat variation. But again, after adjustment for heart rate, no material 
change of outcome was noted. 
As in other studies we see a difference in prognostic value of heart rate 
predominantly in males and less in females (6-12). As far as we know there is no 
good explanation for this phenomenon based upon biological differences between 
males and females. Suggestions in the literature of a protective effect of estrogens 
in females will not likely be the explanation for the difference found in our cohort. 
Other suggestions postulated a lower mortality risk for cardiovascular causes in 
females compared to males because of the absolute lower cardiovascular mortality. 
Although this could be partly true for middle-aged women, in our cohort more 
females died than men. In addition, our finding that prognostic value of heart rate 
for all cause mortality is higher than for cardiovascular mortality is of interest. It 
suggests that heart rate is an epiphenomenon of a more generalized process than 
cardiovascular disease alone. However, we do not know what the underlying 
process might be. 
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Within this population-based study of the oldest old, we were not able to correct for 
potential influences on the parasympathetic/sympathetic balance. ECG recording 
could be in the morning or the afternoon, no information of usage of caffeine 
is available, no information is available if there was physical effort shortly for 
ECG recording, and so forth. Therefore we did not correct for medication either, 
though numerous medications can influence the parasympathetic/sympathetic 
balance. We used the pragmatic view that whatever the cause of the findings on 
the ECG, modification of the parasympathetic/sympathetic balance is reflected in 
the overall survival. 
Our study is very suitable for investigating the predictive value of the ECG 
characteristics, because we used a cohort of elderly without selection and had 
therefore a broad variation of persons and person characteristics. On the other 
hand the causality of our findings is more difficult to interpret. Another strength 
of our study is the multiple assessments of heart rate, ventricular extrasystoles 
and heart rate variability with a follow-up period of 1 year maximum. If heart 
rate variability deteriorates prior to an event the most recent ECG would 
be the one to investigate. This contrasts with other studies in which a single 
electrocardiogram has been associated with (very) long periods of follow-up, 
allowing misclassification to occur. A weakness of our study is that we did not 
have the ability to compare the heart rate variability as measured on a standard 
electrocardiogram with a 24-hour recording.  
Sympathetic dominance as reflected in high heart rate and occurrence of ventricular 
extrasystoles is significantly associated with increased overall mortality. However, 
neither heart rate variability nor AAD was predictive of cardiovascular or non-
cardiovascular mortality.
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The hazardous effect of high blood pressure in people of middle age is a well 
known fact. Moreover, there is ample evidence from randomised clinical trials 
that favour treatment of high blood pressure. In contrast, there is a substantial 
amount of observational data that high blood pressure in elderly people above 
age 80 years is not associated with excess morbidity and or mortality. [1-6] In 
order to explain these apparent discrepancy, there must be a threshold beyond 
which treatment of hypertension does not provide benefit. However, it is difficult 
to understand the nature of this threshold, as age alone is not likely to explain for 
the paradox. After all, physiological systems are not bound to age. In this chapter 
the results of our research in the Leiden 85-plus Study are used to disentangle 
these seemingly contradictory findings in the very old. 
The first objective of this thesis was to explore the association between high 
blood pressure, morbidity and mortality in a very old population. A diagnosis 
of hypertension at age 85 years was predictive of a 50% higher cardiovascular 
mortality during a five years follow-up period.[7] Remarkable, this increased risk 
was independent of the actual blood pressure and known cardiovascular diseases 
at age 85 years. No association was found between high systolic or diastolic blood 
pressure and mortality (total or cardiovascular). Unexpectedly, low systolic blood 
pressure concordant with a low diastolic blood pressure was associated with a 
two-fold increased risk of total mortality. These observations were irrespective 
of gender, current cardiovascular diseases and usage of antihypertensive drugs. 
In chapter 3, the effect of blood pressure on renal function at old age was examined.
[8] High systolic blood pressure was not associated with an accelerated decline of 
creatinine clearance. However, a decline in systolic and diastolic blood pressures 
over a five year period correlated with a 50% increased decline of creatinine 
clearance when compared to those with a stable blood pressure. Thus, at old age, 
high blood pressure was not a risk factor for renal dysfunction. In fact, a decrease 
of blood pressure at old age was associated with an increased decline of renal 
function.
In chapter 4 the relationship between baseline blood pressure and cognitive 
function later in life was examined across age groups from two independent 
population-based cohort studies. [9] Systolic and diastolic blood pressures were 
measured at baseline; cognitive function was assessed at the end of follow-up. In 
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the youngest age group (<65 years), systolic and diastolic blood pressures were 
not associated with cognitive function 11 years later. For persons aged 65-74 years, 
higher systolic and diastolic blood pressures at baseline were related to a decline 
in cognitive function 11 years later. In contrast, in older age (over 75 years) higher 
systolic and diastolic blood pressures were related with higher cognitive function 
11 years later. This effect appeared to be strongest in the highest age group (85 
years). Thus, the relation between baseline blood pressure levels and cognitive 
function later in life differs across age groups. High blood pressure increases the 
risk of cognitive impairment up to 75 years but may preserve cognitive function 
thereafter. 
I conclude that high blood pressure is not related with excess mortality at age 
85 years and over. High blood pressure has a preservative effect on creatinine 
clearance and finally high blood pressure seems to have a preservative effect on 
global cognition after age 75 years that is more pronounced after age 85 years. 
These observations point at a beneficial effect of high blood pressure in old age. 
The alternative hypothesis being that reversed causality is in play. Indeed, various 
chronic and cardiovascular diseases are associated with lower blood pressure and 
higher mortality rates. However, all the correlations reported here were corrected 
for the presence of cardiovascular and chronic diseases and the beneficial effects 
of high blood pressure still stand out. Moreover, reversed causality could explain 
for the relation between lower blood pressure and higher mortality risk, it is less 
likely to explain for the accelerated organ dysfunction that is described.
The second objective was to gain insight into the association between blood 
pressure and cardiac function at high age. Therefore, echocardiography 
examinations were performed in persons at 90 years of age. A first remarkable 
finding in the echocardiographic study was a high prevalence of significant 
mitral and aortic regurgitation. The combined prevalence of significant valvular 
disease was 70%.[Chapter 6] From a clinical perspective, it is noteworthy that 
our participants had little physical restrictions which points to limited impact 
of the valvular disease on the activities of daily living. As the echocardiograpic 
examinations were not thorough enough to make a reliable estimation of the 




the echocardiographic examinations of subjects who were free from significant 
valvular abnormalities to examine the association between blood pressure and 
cardiac output. Overall, the mean cardiac index was low, as was the mean stroke 
volume and both were significantly correlated with systolic blood pressure. [10] A 
lower systolic blood pressure correlated with lower cardiac index and lower stroke 
volume. Left ventricular end-diastolic and left ventricular end-systolic dimensions 
were within reference values and were not related to blood pressure. The mean 
left ventricular ejection fraction was normal and positively associated with blood 
pressure. The average E/A ratio was low also, indicating a high prevalence of 
diastolic dysfunction. Heart rates were significantly higher in participants with a 
lower stroke volume, compared to those with a higher stroke volume. 
To examine the role of the autonomic nervous system associating with mortality, 
annually conducted electrocardiograms were studied. [11] A diminished 
parasympathetic dominance as measured with low heart rate variability did not 
show an association between mortality. Higher heart rate and the occurrences of 
ventricular extrasystoles, both presentations of excess sympathetic activity, were 
associated with an increased mortality. The dominance of the sympathetic nervous 
system could be either a result of an autonomous decrease in parasympathetic 
activity or a systemic adaptation to an underlying process. 
Taken together I conclude that systolic function was preserved but there was a 
high prevalence of diastolic dysfunction and a decreased cardiac index. A lower 
systolic blood pressure was associated with a lower cardiac index and higher heart 
rate. Moreover, an activated sympathetic nervous system was associated with an 
increased mortality. An integrated physiological explanation of these findings 
could lead to the following interpretation. To compensate for a diminished stroke 
volume, heart rate will increase consequent on stimulation of the sympathetic 
nervous system. The elevated heart rate that co-occurs with a lower cardiac index 
fits a systemic adaptation to cardiac dysfunction. Thus, in the populations of older 
people that we have studied, a lower systolic blood pressure will likely mark 
imminent heart failure. 
The observational data that are presented in this thesis showed that high blood 
pressure (both systolic and diastolic) was not related with excess morbidity 
and mortality. On the other hand, low blood pressure was related with excess 
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morbidity and mortality. As earlier stated, it is difficult to imagine that there is 
a certain age after which high blood pressure is beneficial instead of harmful. 
However, if low blood pressure is the result of a decreased cardiac output it could 
facilitate general hypoperfusion and hence explain the hazardous effect of low 
blood pressure at old age. Mean blood pressure rises with age and systolic blood 
pressure continues to rise whereas from the fifth and sixth decade of live diastolic 
blood pressure tends to lower.[12,13] This phenomenon is explained by a stiffer 
vascular system, particularly of the aorta. It is logical that in light of generalised 
atherosclerosis and increased vascular resistance, blood pressure raises to 
compensate for a decline in perfusion of vital organs. In an aging population, the 
prevalence of generalised atherosclerosis will be higher and therefore the risk of 
hypoperfusion will be increased. The recently published HYVET trial, that had 
positive results of treating high blood pressure in persons above 80 years old, 
is at first sight incongruent with our hypothesis. [14] However, the participants 
in the HYVET trial had considerably less cardiovascular disease (12%) when 
compared to the general population of the same age [60%, Chapter 2, this thesis]. 
Additionally, the mortality risk was considerably less then expected for that age 
group. Here I put forward the hypothesis that it was the healthiest people that 
were recruited into the HYVET trial for whom a benefit has been proven. This fits 
with the original inclusion criterion to exclude people with isolated hypertension 
that results of arterial stiffening and atherosclerosis. At older age this is the most 
common form of hypertension. Therefore, the results support treatment of people 
over the age of eighty that do not suffer from significant cardiovascular disease. It 
is however, difficult to generalize these results to older people in the population at 
large amongst which the presence of generalised atherosclerosis is the rule rather 
than the exception. 
It is tempting to speculate how to select the people at old age who will benefit 
from the treatment of high blood pressure. Most persons will not fulfil the 
inclusion criteria of the HYVET, especially persons with a high cardiovascular 
risk. This being the case, what selection criterion should be used to select a healthy 
elder person? Most likely those with a high blood pressure concordant with a 
normal cardiac output should be treated rigorously. Alternative those with a high 
blood pressure concordant with a low cardiac output should not be treated. Pulse 




stiffer vascular tree and therefore a higher risk of hypoperfusion when high blood 
pressure is being lowered. Once treatment is started, the following question is to 
what extent blood pressure should be lowered. What are the treatment goals? The 
international guidelines on treatment of hypertension propose to lower the blood 
pressure to the lowest possible values, but in any case systolic blood pressure 
should be lower then 140 mmHg. If these treatment goals would also suit the 
older population we should institute a far more aggressive treatment than is 
currently applied. But negative outcomes of intensive treatment of high blood 
pressure have been observed among middle-aged people with severe vascular 
disease. [15] In an aged population, it is expected that the hazardous effects of 
aggressive treatment of high blood pressure will be even more pronounced. 
As reported in the HYVET study, mortality risk from stroke was considerably 
lower in the treated versus placebo group. As stroke is a major risk factor for 
cognitive decline one should expect in the treated group positive results for 
maintaining cognition. Remarkably, there was no benefit on cognition in the 
participants with versus those without treatment for hypertension. [16] Though 
the follow-up might have been to short to reveal an effect on cognition there 
could be an alternative explanation. In line with our hypothesis it could very 
well be that active treatment, in this apparently healthy cohort, induced cerebral 
hypoperfusion. The beneficial effect of the reduced stroke incidence might have 
been traded off with cerebral hypoperfusion, with as a result a negligible effect on 
cognition.
In conclusion, the population-based reports indicating lower mortality and 
morbidity risks in association with high blood pressure in the very old are robust 
and cannot be ignored. [1-9] The results of interventional trials, including the 
recent HYVET trial, provide a solid body of evidence also.[14] This thesis supports 
the notion that clinicians should not base treatment of high blood pressure in older 
people on cut-off levels only. Clinicians have to make a decision whether high 
blood pressure in a particular patient is appropriate or not. My hypothesis is that 
high blood pressure concordant with a low cardiac output should not be treated 
in contrast with high blood pressure concordant with a normal/high cardiac 
output. According the Hippocratic Oath, clinicians have to prescribe medication 
for the good of their patients according their best ability and judgment without 
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doing harm. For the time being, treatment of high blood pressure in the very 
old is a clinical challenge with little general rules and highly individualized. It 
goes without saying that, future randomised controlled trials should focus on the 






1 Boshuizen HC, Izaks GJ, Van Buuren S, Ligthart GJ. Blood pressure and mortality 
in elderly people aged 85 and older. BMJ 1998;316:1780-4
2 Lernfelt B, Svanborg A. Change in blood pressure in the age interval 70-90. Late 
blood pressure peak related to longer survival. Blood Pressure 2002;11:206-12
3 Heikinheimo RJ, Haavisto MV, Kaarela RH, Kanto AJ, Koivunen MJ, Rajala SA. 
Blood pressure in the very old. J Hypertens 1990;8:361-7
4 Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure and 
mortality in old persons. Arch Int Med 2000; 160:2765-72
5 Rajalo S, Haavisto M, Heikinheimo R, Mattila K. Blood pressure and mortality in 
the very old. Lancet 1983; 322:520-1
6 Rastas S, Pirttilä T, Viramo P, et al. Association between blood pressure and 
survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc 
2006;54:912-8
7 Van Bemmel T, Gussekloo J, Westendorp RGJ, Blauw GJ. In a population-based 
prospective study, no association between high blood pressure and mortality after 
age 85 years. J Hypertension 24:287-292, 2006
8 Van Bemmel T, Woittiez K, Blauw GJ, van der Sman-de Beer F, Dekker FW, 
Westendorp RGJ, et al. Prospective study of the effect of blood pressure on renal 
function in old age: The Leiden 85-plus Study. J Am Soc Nephrol 2006; 17:2561-2566
9 Euser SM, van Bemmel T, Schram MT, Gussekloo J, Hofman A, Westendorp RGJ, 
Breteler MMB. The effect of age on the association between blood pressure and 
cognitive function later in life. J Am Geriatr Soc 2009 Apr 21. [Epub ahead of print]
10 van Bemmel T, Holman ER, Gussekloo J, Blauw GJ, Bax JJ, Westendorp RG. Low 
blood pressure in the very old, a consequence of imminent heart failure.The 
Leiden 85-plus Study. J Hum Hypertens. 2009 Jan;23(1):27-32.
11 Bemmel van T, Vinkers DJ, Macfarlane PW, Gussekloo J, Westendorp RGJ. Markers 
of autonomic tone on a standard ECG are predictive of mortality in old age. Int J 
Cardiol 2006;107:36-41
12 Franklin SS, Gustin IV W, Wong ND, Larson MG, Weber MA, Kannel WB, 
et al. Hemodynamic patterns of age-related changes in blood pressure. The 
Framingham heart study. Circulation 1997;96:308-15
13 Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in 
the elderly: the Framingham Study. J Hypertens Suppl. 1988;6:S3-9.
Chapter 8
132
14 Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 
years of age or older. N Engl J Med; 2008; 358:1887-98.
15 Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, 
Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure 
in hypertensive patients with coronary artery disease be dangerous? Ann Intern 
Med 2006;144(12):884-93
16 Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure 
lowering in the Hypertension in the Very Elderly Trial cognitive function 










This chapter contains a short review of the history of high blood pressure. The 
changing perspective in time of the hazardous effect of high blood pressure is 
highlighted. In the last 3 decades there has been an explosion in knowledge about 
high blood pressure. As a result of that treatment goals have been stricter and goal 
populations have been broader. However, the evidence of a hazardous effect of 
high blood pressure in the elderly is not robust and even contradictory compared 
to middle-aged people. To explore this possible contradiction this thesis has two 
aims. First it contributes to observational evidence between high blood pressure at 
older age and adverse outcomes, including cardiovascular mortality, renal failure 
and cognitive decline. Secondly, it tries to disentangle the association between 
blood pressure and cardiac function at older age.
Chapter 2
The aim of chapter 2 is to study the impact of a history of hypertension and current 
blood pressure on mortality in the most elderly. This study was part of the Leiden 
85-plus Study, an observational population-based cohort study in the community 
city of Leiden, the Netherlands. Five hundred and ninety-nine inhabitants of the 
birth-cohort 1912-1914 were enrolled on their 85th birthday. There were no selection 
criteria related to health or demographic characteristics. The mean follow-up 
was 4.2 years. Five hundred and seventy-one participants were included, 39 
% had a history of hypertension. During follow-up 290 participants died, 119 
due to cardiovascular causes. Compared to participants without a history of 
hypertension, those with a history of hypertension had a 60% increased mortality 
risk from cardiovascular causes, but equal mortality risks from all causes. High 
blood pressure at age 85 years was not a risk factor for mortality irrespective of 
a history of hypertension. However, blood pressure values below 140/70 mmHg 
(n=48) at age 85 years were associated with excess mortality, predominantly in 
participants with a history of hypertension. Thus, in the most elderly, high blood 
pressure is not a risk factor for mortality, irrespective of a history of hypertension. 




The aim of chapter 3 is to study the effect of blood pressure on creatinine clearance 
over time in very old participants. High blood pressure is associated with a decline 
in renal function. Whether this is true for very old people is largely unknown. 
This study was part of the Leiden 85-plus Study. For this study 550 subjects (34% 
men) were enrolled at their 85th birthday and followed until death or age 90. 
Blood pressure was measured twice at baseline and at age 90 years. Creatinine 
clearance was estimated annually (Cockcroft-Gault formula). The mean creatinine 
clearance at baseline was 45 ml/min. Systolic blood pressure was not associated 
with changes in creatinine clearance during follow-up. Those with diastolic blood 
pressure below 70 mmHg had a significant accelerated decline of creatinine 
clearance compared with those with higher diastolic blood pressure. Participants 
with a decline in systolic blood pressure during follow-up had a significant 
accelerated decline of creatinine clearance compared with those with stable blood 
pressures. Similar results were found for a decline in diastolic blood. Thus, in this 
study high blood pressure at older age is not associated with renal function. In 
contrast, low diastolic blood pressure is associated with an accelerated decline of 
renal function. 
Chapter 4
The aim of this chapter is to determine the prospective relationship between blood 
pressure and cognitive function across a wide age range. This study was part of 
the Rotterdam Study and the Leiden 85-plus Study, both prospective population-
based cohort studies.
Three thousand seventy-eight men and women, initial age 55 to 84 years from 
the Rotterdam Study and 276 men and women, initial age 85 years, from the 
Leiden 85-plus Study were included. Systolic blood pressure and diastolic blood 
pressure were measured at baseline; cognitive function was assessed at the end 
of follow-up using a dedicated neuropsychological test battery. In the youngest 
participants (<65 years), systolic and diastolic blood pressure were not associated 
with cognitive function 11 years later. For persons aged 65 to 74 years, higher 
baseline systolic and diastolic blood pressures were related to worse cognitive 
function 11 years later. In contrast, in older age (≥75 years), higher systolic and 




end of follow-up. This effect appeared strongest in the highest age group (85 
years). Thus, high blood pressure was associated with greater risk of cognitive 
impairment in persons younger than 75 but with better cognitive function in older 
persons. 
Chapter 5
The aim of this study is to elucidate the underlying mechanism of the observational 
findings that low blood pressure in the very old is associated with organ 
dysfunction and excess mortality. We hypothesized that cardiac dysfunction 
contributes to low blood pressure in the very old. A sample of 82 participants all 
aged 90 years from the Leiden 85-plus Study, were invited. Blood pressure was 
measured twice and all but one underwent echocardiography to assess cardiac 
dimensions and functional cardiac parameters. Some 47 participants were free 
from hemodynamically significant valvular disease and were included in the 
present analyses. There were low values for mean cardiac output (2.0 l/min/m2) 
and mean stroke volume (31 ml/m2). For every 10-mmHg decrease in systolic 
blood pressure, cardiac output and stroke volume were significantly lower. 
Mean left ventricular ejection fraction was normal and higher for each 10-mmHg 
decrease in systolic blood pressure. Mean left ventricular dimensions were normal 
but the E/A ratio was 0.68 indicating diastolic dysfunction. In conclusion, among 
the most elderly, low systolic blood pressure correlates with low cardiac output 
while systolic ventricular function is not impaired.
Chapter 6
This study evaluates the prevalence of significant left-sided valvular heart disease 
in community dwelling nonagenarians. In addition, we evaluated the impact of 
valvular heart disease on the ability to perform activities of daily living. Nested 
within the Leiden 85-plus Study a sample of 81 nonagenarians was recruited. 
The left ventricular (LV) dimensions, function and the presence and severity of 
heart valvular disease were evaluated by echocardiography. Daily life activities 
were assessed using the Groningen Activity Restriction Scale (GARS). LV cavity 
diameters and systolic LV function were within normal for the majority of the 
participants. Significant valvular disease was present in 57 (70%) individuals, 
with mitral regurgitation and aortic regurgitation being mostly affected (73% 
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and 47% respectively). The GARS score between individuals with and without 
significant valvular heart disease was similar. In conclusion, the majority of the 
nonagenarians from the general population have significant valvular heart disease 
that does not affect the ability to perform activities of daily living.
Chapter 7
This study investigated markers of autonomic tone on a standard electrocardiogram 
in relation to mortality in old age. This study was part of the Leiden 85-plus Study. 
A total of 599 inhabitants were enrolled in a population-based follow up study at 
their 85th birthday. Electrocardiograms were taken on entry and annually thereafter. 
Electrocardiograms were analysed automatically to determine four markers 
of autonomic tone, i.e. heart rate, the occurrence of ventricular extrasystoles 
and two time domain measures of heart rate variability. All participants were 
followed up for mortality. For those participants with a heart rate in the highest 
quartile the total mortality risk was 1.8-fold increased. However, they had not an 
increased cardiovascular mortality risk. The occurrence of at least one ventricular 
extrasystole was related with a 2.3-fold increased total mortality risk and a 3.6-
fold increased cardiovascular mortality risk. In stratified analyses, the prognostic 
effect was confined to males. Both measures of heart rate variability were not 
related to mortality. Thus, on a standard 10 sec. Electrocardiogram, high heart 
rate and the occurrence of a ventricular extrasystole, both markers of sympathetic 
dominance, were predictive for mortality in old age. Two short-term measures of 
heart rate variability as measured on a standard 10 sec. electrocardiogram were 
not related to mortality, and hence may not reflect autonomic tone in old age. 
Chapter 8
This chapter reveals a general discussion about the hazardous effect of high blood 
pressure in the elderly. The population-based reports indicating lower mortality 
and morbidity risks in association with high blood pressure in the very old are 
robust and should not be ignored. However, the results of the only randomised 
double blind interventional trial done, is solid too. Possibly, high blood pressure 
concordant with a low cardiac output is a different entity compared with high 
blood pressure concordant with a normal/high cardiac output. This might explain 




benefit from treatment of high blood pressure. In contrast, those with a huge 
amount of atherosclerosis / vascular disease might not benefit from treatment, 
due to decreased perfusion, especially in those persons with a decreased cardiac 
output. Clinicians have to make a decision whether the blood pressure in a 
particular patient is appropriate or not. Our hypothesis is that high blood pressure 
concordant with a low cardiac output should not be treated in contrast with high 
blood pressure concordant with a normal/high cardiac output. Therefore, at 
present, we propose that treatment of high blood pressure in the very old is not 
withheld but highly individualized. In our opinion, future research should focus 











In dit hoofdstuk wordt kort de geschiedenis van hoge bloeddruk belicht. Met 
name zal het gewijzigde perspectief over de effecten van hoge bloeddruk door 
de eeuwen worden belicht. De laatste decennia is er een explosieve toename van 
kennis over hoge bloeddruk. Het gevolg daarvan is dat de behandelingsdoelen 
van hoge bloeddruk steeds strikter zijn geworden. Momenteel geldt bijna het credo 
hoe lager de bloeddruk hoe beter, onafhankelijk van de leeftijd. Problematisch is 
dat de meeste kennis van de effecten van hoge bloeddruk en de behandeling van 
hoge bloeddruk is opgedaan bij mensen van middelbare leeftijd. Bij mensen boven 
de 80 jaar is het bewijs dat hoge bloeddruk een risicofactor is voor de gezondheid 
verre van geleverd. Sterker nog, er zijn aanwijzingen dat een lagere bloeddruk bij 
ouderen juist een risicofactor voor ziekte en sterfte is. Dit proefschrift is geschreven 
om meer kennis te vergaren over de effecten van hoge bloeddruk bij ouderen. Het 
eerste doel van dit proefschrift is, om met behulp van observationele studies de 
gevolgen van hoge bloeddruk op sterfte, nierfunctie en cognitie te onderzoeken. 
Het tweede doel van dit proefschrift is om de samenhang tussen de bloeddruk en 
de hartfunctie nader te onderzoeken.
Hoofdstuk 2
In dit hoofdstuk is onderzocht of een voorgeschiedenis van hoge bloeddruk in 
relatie met de huidige bloeddruk een voorspeller is van vroegtijdig overlijden. 
Deze studie was onderdeel van de Leiden 85-plus studie, een observationale 
studie van alle inwoners van Leiden uit het geboortecohort 1912-1914. In totaal 
deden er 599 inwoners mee met de studie. Er waren geen selectie criteria met 
betrekking tot gezondheid of sociale omstandigheden. De gemiddelde duur 
dat de deelnemers werden gevolgd was 4,2 jaar. Van de 599 inwoners konden 
er 571 meedoen met deze studie, 39% had een medische voorgeschiedenis met 
hoge bloeddruk. Gedurende de studie overleden er 290 deelnemers, waarvan 
119 ten gevolge van hart en vaatziekten. Vergeleken met de deelnemers zonder 
een medische voorgeschiedenis van hoge bloeddruk, hadden de deelnemers met 
een medische voorgeschiedenis van hoge bloeddruk een 60% verhoogd risico om 
te overlijden aan hart en vaat ziekten. De totale sterftekans was overigens niet 
verschillend tussen beide groepen. Hoge bloeddruk vanaf een leeftijd van 85 jaar 
was niet voorspellend voor een verhoogde kans op sterven, onafhankelijk van een 
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voorgeschiedenis met hoge bloeddruk. Een bloeddruk lager dan 140/70mmHg 
(totaal 48 deelnemers) was wel voorspellend voor een verhoogde sterfte, en 
dan met name in de deelnemers met een voorgeschiedenis van hoge bloeddruk. 
Kortom, in deze studie bij 85 jarigen is een hoge bloeddruk niet voorspellend voor 
sterfte, een lage bloeddruk is dat wel.
Hoofdstuk 3
In dit hoofdstuk is de relatie tussen de nierfunctie en bloeddruk over de tijd 
onderzocht in ouderen mensen. Hoge bloeddruk is geassocieerd met een snellere 
daling van de nierfunctie. Of dat ook waar is in ouderen is onbekend. Deze 
studie maakte deel uit van de Leiden 85-plus studie. Uiteindelijk konden voor 
deze studie 550 deelnemers (34% mannelijk) van 85 jaar worden gevolgd tot 
overlijden of het bereiken van de leeftijd van 90 jaar. De bloeddruk werd gemeten 
op het 85ste jaar en op het 90ste jaar. De nierfunctie werd geschat met behulp de 
Cockcroft-Gault formule waarbij de kreatinine klaring kan worden berekend. De 
gemiddelde kreatinineklaring was 45ml per minuut. De bovendruk (systolische 
bloeddruk) was niet geassocieerd met de kreatinine klaring gedurende de studie. 
De deelnemers waarvan de onderdruk (diastolische bloeddruk) lager was dan 
70 mmHg hadden een versnelde daling van de kreatinineklaring vergeleken met 
de deelnemers met een hogere diastolische bloeddruk. Deelnemers waarvan 
de systolische bloeddruk daalde tijdens de studie hadden ook een versnelde 
achteruitgang van de kreatinineklaring vergeleken met de deelnemers waarvan 
de bloeddruk gedurende de studie stabiel bleef. Dezelfde resultaten werden 
gezien bij de deelnemers waarvan de diastolische bloeddruk daalde gedurende 
de studie. Concluderend, in deze studie was een hoge bloeddruk bij ouderen 
mensen geen risicofactor voor een versnelde achteruitgang van de nierfunctie. 
Een lage bloeddruk, of een dalende bloeddruk was wel voorspellend voor een 
versnelde achteruitgang van de nierfunctie.
Hoofdstuk 4
Het doel van deze studie is om prospectief de relatie tussen cognitie en bloeddruk 
te onderzoeken in een qua leeftijd brede populatie. Deze studie maakt gebruik 
van de gegevens van de Rotterdam studie en de Leiden 85-plus studie, beide 




de gegevens van 3078 mannen en vrouwen met een leeftijd tussen de 55 en 84 
jaar gebruikt. Vanuit de Leiden 85-plus studie zijn de gegevens van 276 mannen 
en vrouwen van 85 jaar gebruikt. De bloeddruk werd gemeten tijdens het begin 
van de studie en de cognitie tests werden aan het eind van de studie gemeten. 
In de deelnemers jonger dan 65 jaar was de bloeddruk niet geassocieerd met 
cognitie tests 11 jaar later. Bij de deelnemers tussen de 65 en 74 jaar was een hoge 
bloeddruk (systolisch en diastolisch) geassocieerd met een slechtere prestatie op 
de cognitie tests 11 jaar later. Bij de oudere deelnemers (75 jaar en ouder) was een 
hoge bloeddruk (systolisch en diastolisch) geassocieerd met een betere prestatie 
op de cognitie tests. Dit effect was het duidelijkst bij de oudste groep deelnemers 
van 85 jaar. Concluderend, hoge bloeddruk is geassocieerd met een in de toekomst 
slechtere prestatie op cognitie tests in mensen jonger dan 75 jaar, maar met betere 
prestaties op cognitie tests bij ouderen.
Hoofdstuk 5
Deze studie heeft als doel om het achterliggende mechanisme te ontrafelen achter 
de observaties dat een lage bloeddruk bij ouderen gepaard gaat met meer ziekte 
en hogere sterfte.
De hypothese was dat een lagere bloeddruk het gevolg zou zijn van hartfalen. 
Vanuit de Leiden 85-plus studie werden 82 deelnemers van 90 jaar onderzocht. 
De bloeddruk werd tweemaal gemeten en een echocardiografie van het hart 
werd gemaakt. Van 47 deelnemers waren de metingen betrouwbaar genoeg 
om te analyseren. De overigen deelnemers hadden ernstig kleplijden waardoor 
functionele parameters niet betrouwbaar gemeten konden worden. 
De cardiac output was gemiddeld laag (2.0 l/min/m2), het slagvolume was ook 
gemiddeld laag (31 ml/m2). Voor elke 10 mmHg lagere systolische bloeddruk 
waren de cardiac output en het slagvolume significant lager. De gemiddelde 
ejectiefractie van de linkerkamer was normaal en hoger voor elke 10 mmHg 
lagere systolische bloeddruk. De dimensies van de linker hartkamer waren 
normaal, maar de E/A ratio was 0,68 dat duidt op een diastolische disfunctie. 
Concluderend, in deze groep ouderen is er een verband tussen een lage cardiac 
output en een lage systolische bloeddruk. Opvallend is dat de systolische functie 




In deze studie is het voorkomen van kleplijden bestudeerd onder mensen van 
90 jaar. Verder is er onderzocht of er een verminderd dagelijks functioneren bij 
deze ouderen samenhangt met significant kleplijden. Als een onderdeel van de 
Leiden 85-plus studie werden 81 deelnemers van 90 jaar gevraagd om mee te 
doen met deze substudie. De functie van het hart, de dimensies van de linker 
hartkamer en de aanwezigheid van kleplijden werden onderzocht met behulp van 
echocardiografie. Het dagelijks functioneren werd geëvalueerd met de “Groningen 
Activity Restriction Scale (GARS)”. De dimensies van het hart en de systolische 
functie van de linkerkamer waren normaal in de meerderheid van de deelnemers. 
Significant kleplijden was aanwezig bij 57 (70%) van de deelnemers. Met name was 
er sprake van mitraalklep insufficiëntie (73%) en aortaklepinsufficiëntie (47%). De 
GARS score was niet verschillend tussen de deelnemers met en zonder significant 
kleplijden. Samenvattend, de meerderheid van de 90 jarigen in de bevolking heeft 
significant kleplijden. Opvallend is dat het kleplijden niet interfereert met het 
dagelijks functioneren.
Hoofdstuk 7
In deze studie werd onderzocht of op het standaard ECG van 10 seconden, markers 
van het autonome zenuwstelsel voorspellend waren voor sterfte bij ouderen. 
Deze studie was onderdeel van de Leiden 85-plus studie. In totaal werden 599 
deelnemers gevolgd vanaf hun 85ste verjaardag. Standaard ECG’s werden jaarlijks 
gemaakt. De ECG’s werden automatisch geanalyseerd op 4 markers van het 
autonome zenuwstelsel; hartfrequentie, de aanwezigheid van ventriculaire 
extrasystole en twee maten van hartritme variabiliteit.  Alle deelnemers werden 
vervolgd tot hun 89ste jaar of  tot aan het overlijden. De deelnemers met de hoogste 
hartfrequentie hadden een 1,8 keer grotere kans om te overlijden vergeleken met 
de andere deelnemers. Opmerkelijk was dat de sterfte aan hart en vaatziekte wel 
gelijk was tussen beide groepen deelnemers. Indien er op het ECG een ventriculaire 
extrasystole aanwezig was, dan was de kans op sterfte 2,3 keer hoger en de kans 
op sterfte aan hart en vaatziekte 3,6 keer hoger vergeleken met de deelnemers 
die geen ventriculaire extrasystole op het ECG hadden. Deze hogere sterfte gold 
overigens alleen voor mannen. De beide maten van hartritme variabiliteit gemeten 




aanzien van sterfte. Waarschijnlijk zijn deze maten bij ouderen niet de reflectie 
van de activiteit van het autonome zenuwstelsel. 
Hoofdstuk 8
Dit hoofdstuk bevat een discussie over het al dan niet schadelijke effect van 
een hoge bloeddruk in ouderen. De observationele bevolkingsonderzoeken 
laten consequent zien dat bij ouderen de kans op sterfte en ziekte bij een hogere 
bloeddruk lager is dan bij een lagere bloeddruk. Maar de enige goed opgezette 
studie naar het effect van behandeling van hoge bloeddruk liet een voordeel zien 
van een bloeddruk verlagende behandeling. Misschien is het zo, dat de het niet 
zo zeer gaat om een hoge bloeddruk maar meer om de onderliggende fysieke 
gesteldheid van het hart- en vaatsysteem.  Het zou kunnen dat een hoge bloeddruk 
samen met een verlaagde cardiac output een hele andere entiteit is dan een hoge 
bloeddruk met een normale cardiac output. Dat zou dan kunnen verklaren dat 
ouderen met maar weinig schade aan hart en vaten een positief effect hebben van 
een behandeling van hoge bloeddruk. Dit overigens in tegenstelling met ouderen 
die wel veel schade hebben aan hart en bloedvaten. Behandeling van een hoge 
bloeddruk van deze laatste groep ouderen zou kunnen leiden tot oversterfte ten 
gevolge van de behandeling. En deze oversterfte zou dan met name zichtbaar 
moeten zijn bij degene met een verlaagde cardiac output. De behandelende dokter 
zal een beslissing moeten maken of een bepaalde hoogte van bloeddruk bij een 
patiënt goed is of niet. Onze hypothese is dat een hoge bloeddruk die samen gaat 
met een verlaagde cardiac output niet zou moeten worden behandeld. Kortom, 
voorlopig, totdat er meer kennis is over de behandeling van hoge bloeddruk bij 
ouderen moet de behandeling daarvan niet worden onthouden maar wel sterk 
worden geïndividualiseerd. Naar onze mening zou verder onderzoek zich onder 
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